Bruker Cellular Analysis (CELL) 10-K 28 Feb 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Feb. 14, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39388
Entity Registrant Name	Berkeley Lights, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2415390
Entity Address, Address Line One	5858 Horton Street, Suite 320
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	858-2855
Title of 12(b) Security	Common stock, par value $0.00005 per share
Trading Symbol	BLI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Public Float			$ 2.3
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		67,651,189
Documents Incorporated by Reference	Portions of the registrant’s Definitive Proxy Statement relating to the registrant’s 2022 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2021.
Entity Central Index Key	0001689657
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	San Francisco, California
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 178,096	$ 233,408
Trade accounts receivable	25,942	12,939
Inventory	14,547	11,047
Prepaid expenses and other current assets	11,985	8,175
Total current assets	230,570	265,569
Restricted cash	270	270
Property and equipment, net	27,992	14,544
Operating lease right-of-use assets	26,060	16,718
Other assets	2,361	2,557
Total assets	287,253	299,658
Current liabilities:
Trade accounts payable	8,198	3,491
Accrued expenses and other current liabilities	12,425	8,401
Current portion of notes payable	0	11,594
Deferred revenue	12,128	5,482
Total current liabilities	32,751	28,968
Notes payable, net of current portion	19,762	8,301
Deferred revenue, net of current portion	2,187	1,709
Operating lease liability, noncurrent	24,337	15,899
Total liabilities	79,037	54,877
Commitments and contingencies (Note 14)
Stockholders’ equity:
Convertible preferred stock, $0.00005 par value. Authorized 10,000,000 shares at December 31, 2021 and 2020, respectively; no shares issued and outstanding at December 31, 2021 and 2020	0	0
Common stock, $0.00005 par value. Authorized 300,000,000 shares at December 31, 2021 and 2020, respectively; issued and outstanding 67,595,535 shares and 64,486,246 shares at December 31, 2021 and 2020, respectively	4	3
Additional paid-in capital	471,820	436,662
Accumulated deficit	(263,608)	(191,884)
Total stockholders’ equity	208,216	244,781
Total liabilities and stockholders’ equity	$ 287,253	$ 299,658

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Convertible preferred stock authorized (in shares)	10,000,000
Convertible preferred stock issued (in shares)	0
Convertible preferred stock outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Common stock authorized (in shares)	300,000,000
Common stock issued (in shares)	67,595,535	64,486,246
Common stock outstanding (in shares)	67,595,535	64,486,246

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 85,388	$ 64,303	$ 56,693
Cost of sales:
Total cost of sales	28,837	19,748	13,217
Gross profit	56,551	44,555	43,476
Operating expenses:
Research and development	58,553	47,240	38,414
General and administrative	43,400	23,202	12,362
Sales and marketing	25,387	14,507	9,237
Total operating expenses	127,340	84,949	60,013
Loss from operations	(70,789)	(40,394)	(16,537)
Other income (expense):
Interest expense	(1,171)	(1,436)	(1,425)
Interest income	175	338	909
Other income (expense), net	6	82	(1,180)
Loss before income taxes	(71,779)	(41,410)	(18,233)
Provision for (benefit from) income taxes	(55)	174	69
Net loss and net comprehensive loss	(71,724)	(41,584)	(18,302)
Net loss and net comprehensive loss	$ (71,724)	$ (41,584)	$ (18,302)
Net loss attributable to common stockholders per share, basic (in dollars per share)	$ (1.08)	$ (1.39)	$ (7.46)
Net loss attributable to common stockholders per share, diluted (in dollars per share)	$ (1.08)	$ (1.39)	$ (7.46)
Weighted-average shares used in calculating net loss per share, basic (in shares)	66,707,129	31,192,752	2,883,950
Weighted-average shares used in calculating net loss per share, diluted (in shares)	66,707,129	31,192,752	2,883,950
Product
Revenue:
Total revenue	$ 56,575	$ 51,586	$ 43,460
Cost of sales:
Total cost of sales	14,857	13,021	11,245
Service
Revenue:
Total revenue	28,813	12,717	13,233
Cost of sales:
Total cost of sales	$ 13,980	$ 6,727	$ 1,972

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2018		50,462,272	2,690,264
Beginning balance at Dec. 31, 2018	$ 97,631	$ 224,769	$ 0	$ 4,860	$ (131,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			382,803
Exercise of stock options	606			606
Vesting of shares subject to repurchase from early exercised options	88			88
Stock-based compensation	3,760			3,760
Net loss	(18,302)				(18,302)
Ending balance (in shares) at Dec. 31, 2019		50,462,272	3,073,067
Ending balance at Dec. 31, 2019	83,783	$ 224,769	$ 0	9,314	(150,300)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of convertible preferred stock into common stock (in shares)		(50,462,272)	50,462,272
Conversion of convertible preferred stock into common stock	0	$ (224,769)	$ 3	224,766
Issuance of common stock upon initial public offering, net of issuance costs (in shares)			9,315,000
Issuance of common stock upon initial public offering, net of issuance costs	187,935			187,935
Cashless exercise of common stock warrants (in shares)			123,192
Exercise of stock options (in shares)			1,512,715
Exercise of stock options	3,585			3,585
Vesting of shares subject to repurchase from early exercised options	328			328
Stock-based compensation	10,734			10,734
Net loss	(41,584)				(41,584)
Ending balance (in shares) at Dec. 31, 2020		0	64,486,246
Ending balance at Dec. 31, 2020	$ 244,781	$ 0	$ 3	436,662	(191,884)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	2,882,470		2,882,470
Exercise of stock options	$ 10,297		$ 1	10,296
Vesting of restricted stock units (in shares)			63,811
Employee stock purchase plan (in shares)			163,008
Employee stock purchase plan	3,644			3,644
Stock-based compensation	21,218			21,218
Net loss	(71,724)				(71,724)
Ending balance (in shares) at Dec. 31, 2021		0	67,595,535
Ending balance at Dec. 31, 2021	$ 208,216	$ 0	$ 4	$ 471,820	$ (263,608)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (71,724)	$ (41,584)	$ (18,302)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	5,598	5,102	4,842
Stock-based compensation	21,222	10,917	3,760
Amortization of operating lease right-of-use assets	2,327	1,691	1,673
Non-cash interest and other expense related to debt and note receivable agreements	67	68	4
Provision for excess and obsolete inventory	678	32	169
Loss on impairment of property and equipment	60	140	782
Change in fair value of embedded derivative	0	0	62
Equity method losses in Optera Therapeutics Corp.	0	0	806
Net loss on dissolution of Optera Therapeutics Corp.	0	0	236
Changes in operating assets and liabilities:
Trade accounts receivable	(13,003)	(3,605)	2,389
Inventory	(6,635)	(4,226)	(4,019)
Prepaid expenses, other current assets and other assets	(3,513)	(1,793)	(4,079)
Trade accounts payable	3,878	373	494
Deferred revenue	7,124	(3,955)	1,634
Accrued expenses and other current liabilities	2,991	2,655	782
Operating lease liability	(2,198)	(1,667)	(1,766)
Net cash used in operating activities	(53,128)	(35,852)	(10,533)
Cash flows from investing activities:
Purchase of property and equipment	(15,825)	(3,289)	(8,423)
Issuance of notes receivable	0	0	(1,000)
Collection of notes receivable	0	0	350
Net cash used in investing activities	(15,825)	(3,289)	(9,073)
Cash flows from financing activities:
Proceeds from issuance of common stock upon initial public offering, net	0	190,585	0
Payment of issuance costs	0	(2,650)	0
Debt issuance costs	(300)	0	0
Proceeds from issuance of common stock upon exercise of stock options	10,297	3,581	606
Proceeds from issuance of common stock under employee stock purchase plan	3,644	0	0
Proceeds from issuance of common stock upon early exercise of stock options	0	0	416
Net cash provided by financing activities	13,641	191,516	1,022
Net increase (decrease) in cash and cash equivalents and restricted cash	(55,312)	152,375	(18,584)
Cash and cash equivalents and restricted cash at beginning of period	233,678	81,303	99,887
Cash and cash equivalents and restricted cash at end of period	$ 178,366	$ 233,678	$ 81,303

The Company and Basis of Presen

The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The company and basis of presentation	The company and basis of presentation Description of business Berkeley Lights, Inc. (the “Company” or “Berkeley Lights”), was incorporated as a Delaware corporation on April 5, 2011. Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights’ platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software. In 2017, Berkeley Lights incorporated BLI Europe International, Ltd. as a wholly-owned subsidiary in the United Kingdom to support Berkeley Lights’ planned expansion in Europe. In the third quarter of 2020, Berkeley Lights established a wholly owned foreign operating entity in China to further expand its operations. In the second quarter of 2021, Berkeley Lights established a subsidiary in Singapore to support its overall sales and service efforts in the Asia Pacific region. Berkeley Lights and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California. The Company commercially launched its platform in December of 2016, which included its Beacon system and the alpha version of its Opto Cell Line Development 1.0 workflow, targeted to the antibody therapeutics market. In June 2019, the Company launched its desktop Lightning system targeted for assay development and lower throughput workflows, and in early 2020 the Company launched the Culture Station instrument. The Company is expanding the capabilities of its platform through the commercial launch of additional workflows in its core markets of antibody therapeutics, cell therapy, gene therapy, agricultural biology and synthetic biology. Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP. Liquidity The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the year ended December 31, 2021, the Company had a consolidated net loss of $71.7 million and as of December 31, 2021, had an accumulated deficit of $263.6 million and unrestricted cash and cash equivalents of $178.1 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of December 31, 2021 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying consolidated financial statements. Reverse stock split On July 10, 2020, the Board of Directors of the Company approved a 1-for-2 reverse stock split of its issued and outstanding common stock and convertible preferred stock, which was effected on July 14, 2020. The par value of the authorized stock was not adjusted as a result of the reverse stock split. Other than the par value, all share and per share data shown in the accompanying consolidated financial statements and related notes have been retroactively adjusted to reflect the reverse stock split for all periods presented. Initial public offering The Company’s registration statement on Form S-1 related to its initial public offering (“IPO”) was declared effective on July 16, 2020 by the SEC, and the Company’s common stock began trading on the Nasdaq Global Select Market on July 17, 2020. On July 21, 2020, the Company closed its IPO, in which the Company sold 9,315,000 shares of common stock (which included 1,215,000 shares that were sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares) at a price to the public of $22.00 per share. Including the

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimate of the standalone selling price of performance obligations and allocation of contract price in multiple-element revenue arrangements, total expected costs associated with development agreements, estimated transaction price, including variable consideration, of the Company’s revenue contracts, accruals for product warranties, the fair value of equity awards and related share-based compensation, the collectability of accounts receivable, valuation of inventory and the realizability of deferred income taxes. Actual results could significantly differ from those estimates. Cash and cash equivalents and restricted cash The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of December 31, 2021 and 2020, restricted cash consists of cash on deposit in a financial institution that is restricted to be used for the Company’s corporate credit card program. The following table provides a reconciliation of cash and cash equivalents and restricted cash on the consolidated balance sheets to the totals presented on the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 178,096 $ 233,408 Restricted cash 270 270 Total cash and cash equivalents and restricted cash as presented on the consolidated statements of cash flows $ 178,366 $ 233,678 Trade accounts receivable Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance and expected credit losses related to its receivables, management considers historical losses adjusted to take into account current market and economic conditions and the Company’s customers’ respective financial conditions, the amounts of receivables in dispute and the current receivables aging and current payment patterns. To the extent identified, account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date its customers have primarily been large biopharmaceutical companies, well known research institutes and related companies and therefore we have not had any material write-offs or allowance for doubtful accounts in the years ended December 31, 2021 and 2020. Inventory Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities and equipment and overhead. Revenue recognition The Company derives revenue from primarily two sources, product and service revenues, which are discussed further below. The Company recognizes revenue using a five step process. This process involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract based on their stand-alone selling price, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company’s agreements with customers often include multiple performance obligations, which can sometimes be included in separate contracts entered into within a reasonably short period of time. The Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Management must apply judgment in determining whether the individual promises represent multiple performance obligations, or a single, combined performance obligation. In order to determine the stand-alone selling price, the Company conducts a periodic analysis to determine whether various goods or services have an observable stand-alone selling price as well as to identify significant changes to current stand-alone selling prices. If the Company does not have an observable stand-alone selling price for a particular good or service, then the stand-alone selling price for that particular good or service is estimated using an approach that maximizes the use of observable inputs. The Company’s process for determining stand-alone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. The Company believes that this method results in an estimate that represents the price the Company would charge for the product offerings if they were sold separately. For most of its performance obligations, the Company has established stand-alone selling price as a range rather than a single value, such range being plus or minus 15% of the weighted average of observable prices. If the contractually stated prices of all the performance obligations in a contract fall within their respective stand-alone selling price ranges, the Company will allocate the transaction price at the contractually stated amounts. In situations where the contractually stated price for one or more performance obligations in a contract fall(s) outside of their respective stand-alone selling price range, the Company will use the mid-point of the respective stand-alone selling price range for performance obligations in the contract priced outside of their respective stand-alone selling price range(s) and the contract values for performance obligations priced within their respective stand-alone selling price range(s), to allocate the transaction price on a relative stand- alone selling price basis. Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales. In certain markets, our products are sold to customers primarily through distributors. The terms of sales transactions to our distributors are substantially consistent with the terms of our direct sales to end customers. The following describes the nature of the Company’s primary types of revenue and the revenue recognition policies and significant payment terms as they pertain to the types of transactions the Company enters into with its customers. Product revenues Product revenues are comprised of two major revenue streams, direct platform sales and consumables. Direct platform sales revenues are comprised of advanced automation systems, which include the Beacon and Lightning systems (including fully paid workflow licenses) as well as Culture Station instruments. Consumables revenues are comprised of OptoSelect chips required to run the system as well as reagent kits. Direct platform sales also include revenue from certain historical subscription arrangements in which customers are able to subscribe to a specific workflow and pay a quarterly fee over a fixed period of time which covers the annual workflow license, the advanced automation system, as well as warranty and service. While the majority of the Company’s revenue under its TechAccess subscription falls into the service category, consumables and certain other deliverables under TechAccess subscription are categorized as product revenue. The Company’s standard arrangement with its customers is generally a purchase order or an executed contract. Revenue on product sales is recognized when control has transferred to the customer which typically occurs when the product has been shipped to the customer, risk of loss has transferred to the customer and the Company has a present right to payment for the system, chip or kit, as applicable. In certain limited circumstances when a product sale includes client acceptance provisions, the Company will first assess such terms to determine if the control of the good is being transferred to the customer in accordance with the agreed-upon specifications in the contract. To the extent that such acceptance provisions can be objectively determined to be aligned with the standard specifications of the arrangement, are defined and easily evaluated for completion, as well as do not afford the customer any additional rights or create additional performance obligations for the Company, such provisions would be determined perfunctory and would not preclude revenue recognition presuming all other criteria are met. If such acceptance provisions are considered to be substantive, revenue is recognized either when client acceptance has been obtained, client acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the client acceptance provisions have been satisfied. Payment terms are generally thirty to ninety days from the date of invoicing. On a limited basis, the Company also enters into fixed-term sales-type lease arrangements with certain qualified customers. Service revenues Service revenues primarily consist of strategic partnerships and services agreements, service and warranty, training and installation services, platform support and feasibility studies on the Company’s advanced automation systems and workflows. Strategic partnerships and services agreements are agreements whereby the Company provides services for, among other things, the development of customized workflows, screening capabilities, or for customized consumables or advanced automation systems to meet a specific customer’s needs. These contracts can be executed on a time-and-materials basis and in certain cases include defined milestones associated with these development activities over extended periods of time, some in excess of twenty-four months. The Company’s services are generally provided primarily on a fixed fee basis with defined billing schedules. The Company reviews strategic partnerships and services agreements for revenue recognition at contract inception and generally recognizes revenue from these contracts over time, using either an input measure of progress based on costs incurred to date relative to total expected costs or on a time and materials basis. The Company recognizes revenue from the sale of extended warranty and enhanced service warranty arrangements over the respective period, while revenue on feasibility studies is recognized over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Revenue on platform support is recognized as the services are performed. Service contracts are typically short-term in nature. Payment terms are generally thirty to ninety days from the date of invoicing. The Company only includes variable consideration in the transaction price to the extent that it is not probable that a significant reversal of revenue will occur for that amount. The constraint estimate is reassessed at each reporting date until the uncertainty is resolved. Contract assets and contract liabilities Contract assets include amounts where revenue recognized exceeds the amount invoiced to the customer and the right to payment is not solely subject to the passage of time. The Company’s contract asset balances of $2.8 million and $2.7 million as of December 31, 2021 and 2020, respectively, are primarily from its sales-type lease arrangements as well as its development and feasibility study agreements. The Company does not have impairment losses associated with contracts with customers for the years ended December 31, 2021 and 2020. Contract liabilities consist of fees invoiced or paid by the Company’s customers for which the associated services have not been performed and revenues have not been recognized based on the Company’s revenue recognition criteria described above. Such amounts are reported as deferred revenue on the consolidated balance sheets. Deferred revenue that is expected to be recognized during the following twelve months is recorded as a current liability and the remaining portion is recorded as non-current. Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term on the consolidated balance sheet based on the timing of when the Company expects to complete the related performance obligations and invoice the customers. Contract liabilities are classified as current or long-term on the consolidated balance sheet based on the timing when the revenue recognition associated with the related customer payments and invoicing is expected to occur. Costs to obtain or fulfill a contract Origination costs relate primarily to sales commissions to individuals that are directly related to sales transactions. Fulfillment costs generally include the direct cost of services such as platform support and feasibility studies. Origination and fulfillment costs that are internal to the Company are generally expensed when incurred because most of those costs are incurred concurrently with the delivery of the related goods and services, which are predominantly recognized at a point in time or are less than one year in nature. The origination costs that are related to long-term development agreements are capitalized and amortized over the relevant service period. The origination costs that are related to long-term development agreements are not material as of December 31, 2021 and 2020. Property and equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation on plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Expenditures for major additions and improvements to property and equipment are capitalized and maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. The estimated useful lives of the Company’s property and equipment are as follows: Equipment, tooling and molds 5—7 years Computer equipment and software 3—7 years Furniture, fixtures and other 3—7 years Leasehold Improvements Shorter of lease term or estimated useful life Other assets Other current assets and other assets consist primarily of contract assets discussed above, prepaid rent, prepaid insurance and advance payments made to certain vendors for future delivery of goods or services and software implementation costs for cloud-based hosting arrangements that are a service contract. The Company expenses all cloud-based hosting arrangement related costs (internal and external) that were incurred in the planning and post-implementation operation stages of such implementations and capitalizes costs related to the application development stage of such projects. Such projects primarily include the implementation of a new customer relationship management system (“CRM system”) and a new enterprise resource planning system (“ERP system”). The capitalized costs are generally amortized on a straight-line basis over the estimated useful life starting on the date that the projects are placed into production and are ready for their intended use. As of December 31, 2021 approximately $0.5 million and $0.5 million were classified in prepaid expenses and other current assets and other assets, respectively. As of December 31, 2020 approximately $0.3 million and $0.6 million were classified in prepaid expenses and other current assets and other assets, respectively. Research and development costs Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, laboratory supplies, materials expenses and allocated facilities costs for employees and contractors engaged in development arrangements, research, regulatory affairs, and product development. The Company expenses all research and development costs in the periods in which they are incurred. Advertising expenses The cost of advertising, marketing and media is expensed as incurred. For the years ended December 31, 2021, 2020 and 2019, advertising expenses totaled $1.2 million, $1.4 million and $1.0 million, respectively. Income taxes The Company’s provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflects its best assessment of estimated future taxes to be paid. The Company’s provision for income taxes consists primarily of foreign taxes and state taxes in the United States. As the Company expands the scale and scope of its international business activities, any changes in the United States and foreign taxation of such activities may increase its overall provision for income taxes in the future. Deferred income taxes comprise the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carryforwards, and other tax credits measured by applying currently enacted tax laws. A valuation allowance is provided when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company’s policy for interest and penalties related to uncertain tax positions is to recognize interest and penalties, if any, as a component of the provision for income taxes in the consolidated statements of operations and to include accrued interest and penalties within the related tax liability line in the consolidated balance sheets. For all periods presented, the Company has provided a valuation reserve equal to 100% of its deferred tax assets as the Company is not in a position to determine if its operating plans will be successful and result in taxable income to absorb any loss carryforwards. Stock-based compensation The Company maintains an incentive compensation plan under which incentive stock options, non-qualified stock options and restricted stock units (“RSU”) are granted primarily to employees and non-employee consultants. Stock-based compensation expense for stock-based awards is based on the grant date fair value of the award. The Company determines the fair value of RSU’s based on the closing value of its stock price listed on the Nasdaq at the date of the grant. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period, provided the grantee remains an employee or consultant of the Company through each applicable vesting date. For performance awards not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, no compensation expense is recognized and any previously recognized compensation expense is reversed. Long-lived assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Fair value measurements The fair value of the Company’s money market funds are based on quoted market prices in active markets for identical assets (see Note 6 to these consolidated financial statements). Product warranties The Company provides a 13-month assurance-type warranty, generally beginning on the shipment date, on its platforms and chip consumables. Upon shipment, the Company establishes an accrual for estimated warranty expenses based on historical data and trends of product reliability and costs of repairing and replacing defective products. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, estimated repair costs, freight, material, labor, and overhead costs. While management believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company’s products could result in actual expenses that are below those currently estimated. Foreign currency translation and transactions The Company has determined that the functional and reporting currency for its operations in the United Kingdom and China is the U.S. Dollar. Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net. Leases The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in rent expense when incurred. The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current a ssets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the consolidated balance sheets. Net loss attributable to common stockholders per share Net loss attributable to common stockholders per share is computed dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. In computing diluted net loss per share, the Company utilizes the treasury stock method. The Company applies the two-class method to compute basic and diluted net loss or income per share when it has issued shares that meet the definition of participating securities. The two-class method determines net (loss) or income per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net (loss) income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net (loss) income for the period had been distributed. The Company’s convertible preferred stock participated in any dividends declared by the Company and were therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method. Recently issued and adopted accounting standards In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxe s, which removes certain exceptions related to intra-period tax allocations and deferred tax accounting on outside basis differences in foreign subsidiaries and equity method investments. Additionally, it provides other simplifying measures for the accounting for income taxes. The Company adopted ASU 2019-12 effective January 1, 2021; such adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures.

Significant Risks and Uncertain

Significant Risks and Uncertainties Including Business and Credit Concentrations	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Significant risks and uncertainties including business and credit concentrations	Significant risks and uncertainties including business and credit concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and trade receivables. The Company’s cash and cash equivalents are held by large, credit worthy financial institutions. The Company invests its excess cash in money market funds. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected as probable credit losses in its existing trade accounts

Revenue From Contract With Cust

Revenue From Contract With Customers	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue from contracts with customers	Revenue from contracts with customers Disaggregation of revenue The following table depicts the disaggregation of revenue by type of customer or sales channel, market segment as defined by nature of workflows and activities of the end customer, and timing of revenue recognition (in thousands): Year ended December 31, 2021 2020 2019 Type of Sales Channel Direct sales channel $ 56,969 $ 58,233 $ 53,014 Distributor channel 28,419 6,070 3,679 Net revenues $ 85,388 $ 64,303 $ 56,693 Market Segment Antibody therapeutics $ 64,317 $ 51,782 $ 49,428 Gene therapy 7,108 — — Agricultural biology 2,183 — — Cell therapy 2,818 4,472 2,550 Synthetic biology 8,962 8,049 4,715 Net revenues $ 85,388 $ 64,303 $ 56,693 Timing of Revenue Recognition Goods and services transferred at a point in time $ 55,389 $ 50,583 $ 43,359 Goods and services transferred over time 29,999 13,720 13,334 Net revenues $ 85,388 $ 64,303 $ 56,693 Revenues by market are determined by the revenue associated with workflows that the Company’s customers are utilizing, primarily on our Beacon platform, or by the nature of the workflows that the Company is developing under strategic partnerships and services agreements. Revenues by geographical markets are presented in Note 18 to these consolidated financial statements. Performance obligations A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less. As of December 31, 2021, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts was $7.2 million, which is included in deferred revenue on the Company’s consolidated balance sheets, of which approximately 48% is expected to be recognized to revenue in the next 12 months, with the remainder afterwards. Contract balances The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): December 31, 2021 2020 Trade accounts receivable $ 25,942 $ 12,939 Contract assets, which are included in “Prepaid expenses and other current assets” $ 1,736 $ 1,310 Contract assets, long-term, which are included in “Other assets” $ 1,070 $ 1,375 Deferred revenue (current) $ 12,128 $ 5,482 Deferred revenue (non-current) $ 2,187 $ 1,709 The contract liabilities of $14.3 million and $7.2 million as of December 31, 2021 and December 31, 2020, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements, and advanced automation system arrangements. Revenue recorded during the year ended December 31, 2021 included $5.3 million of previously deferred revenue that was included in contract liabilities as of December 31, 2020. Sales-type lease arrangements The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was $2.7 million and $1.7 million for the year ended December 31, 2021 and 2020, respectively. The Company recorded no sales-type lease arrangement revenue in the year ended December 31, 2019. The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of December 31, 2021 (in thousands): Year ending December 31, Sales-Type 2022 $ 2,548 2023 445 2024 and thereafter 853 Total undiscounted cash flows 3,846 Less: unearned income (439) Total amounts due from customers, gross $ 3,407

Balance Sheet Accounts

Balance Sheet Accounts	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance sheet accounts	Balance sheet accounts Inventory The following table shows the components of inventory (in thousands): December 31, 2021 2020 Raw materials $ 8,296 $ 6,675 Finished goods 6,251 4,372 Total $ 14,547 $ 11,047 Prepaid expenses and other current assets The following table shows the components of prepaid expenses and other current assets (in thousands): December 31, 2021 2020 Contract asset $ 1,736 $ 1,310 Vendor deposits 2,802 1,346 Deferred costs 561 292 Prepaid insurance 2,944 2,401 Other (1) 3,942 2,826 Total $ 11,985 $ 8,175 (1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT. Accrued expenses and other current liabilities The following table shows the components of accrued expenses and other current liabilities (in thousands): December 31, 2021 2020 Accrued payroll and employee related expenses $ 6,757 $ 4,152 Lease liability—short-term 2,941 1,909 Accrued product warranty 1,085 1,271 Accrued legal expenses 504 606 Other 1,138 463 Total $ 12,425 $ 8,401

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value of financial instruments	Fair value of financial instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate fair value due to their relatively short maturities. The Company classifies its cash equivalents, which are comprised primarily of money market funds, within Level 1, as it uses quoted market prices in the determination of fair value. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): December 31, 2021 Quoted prices Significant Significant Assets Money market funds $ 25,138 $ 25,138 $ — $ — Total $ 25,138 $ 25,138 $ — $ — December 31, 2020 Quoted prices Significant Significant Assets Money market funds $ 25,133 $ 25,133 $ — $ — Total $ 25,133 $ 25,133 $ — $ — The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): December 31, 2021 2020 Carrying Fair value Carrying Fair value Long-term debt, including current maturities $ 19,762 $ 19,298 $ 19,895 $ 19,949 The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy.

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and equipment, net	Property and equipment, net Property and equipment, net comprised the following (in thousands): December 31, 2021 2020 Equipment, tooling and molds $ 33,972 $ 21,118 Computer software and equipment 3,019 2,153 Furniture, fixtures and other 1,891 1,739 Leasehold improvements 6,105 5,597 Construction in process 4,803 275 Total property and equipment $ 49,790 $ 30,882 Less: accumulated depreciation (21,798) (16,338) Property and equipment, net $ 27,992 $ 14,544

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, distribution and laboratory facilities in Emeryville, California under multiple operating leases totaling approximately 84,502 square feet. During the third quarter of 2021, the Company extended the term for its leases related to the facilities in Emeryville and these leases will now expire in 2029. Also, during the third quarter of 2021, the Company entered into a seven year lease of space for office and laboratory operations in Lexington, Massachusetts, which commended on July 1, 2021. The Company also leases two facilities in Shanghai, China for office and laboratory facilities under operating lease agreements that were entered into in July 2020. These leases expire at various dates, the latest of which is August 2023. Future payments associated with the Company’s operating lease liabilities as of December 31, 2021 are as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, 2022 $ 4,202 2023 4,276 2024 4,355 2025 4,486 2026 4,621 Thereafter 12,223 Total undiscounted lease payments 34,163 Less: implied interest (5,459) Less: tenant improvement allowance receivable (1,426) Present value of operating lease payments 27,278 Less: current portion (1) (2,941) Total long-term operating lease liabilities $ 24,337 (1) Included in the balance sheet caption “Accrued expenses and other current liabilities.” Rent expense for the years ended December 31, 2021, 2020 and 2019 was $3.8 million, $2.6 million and $2.2 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $2.3 million, $1.6 million and $1.0 million for the years ended December 31, 2021, 2020 and 2019, respectively, including non-lease components such as common area maintenance fees. The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Year ended December 31, 2021 Right-of-use assets obtained for new operating lease liabilities - New leases $ 3,348 Right-of-use assets obtained in exchange for new operating lease liabilities - Modification of existing leases $ 8,320 Cash paid for amounts included in the measurement of lease liabilities $ 3,675 The following summarizes additional information related to operating leases: Year ended December 31, 2021 Weighted-average remaining lease term (years) 7.51 Weighted average discount rate 4.67 %

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes payable	Notes payable On May 23, 2018, the Company entered into a Loan and Security Agreement with East West Bank (“EWB”) providing it the ability to borrow up to $20.0 million. The loan facility was fully drawn as of May 23, 2018. On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (the “Agreement”) with EWB. Pursuant to the Agreement, EWB provided a $20.0 million term loan (“the Term Loan”) which was used to refinance the term loan outstanding under the Loan and Security Agreement dated May 23, 2018. The Term Loan matures in 48 months and bears interest at a fixed rate of 4.17%. The Term Loan has an initial interest-only period of 24 months, which can be extended to up to 36 months based on the achievement of certain liquidity measures, and can be pre-paid without penalty at any time. The Agreement grants EWB a security interest in and liens on all assets of the Company, excluding intellectual property, which is subject to a double negative pledge. In addition, certain other terms of the original agreements as previously in effect were amended by the Agreement, including certain financial covenants. The Amended and Restated Loan and Security Agreement was accounted for as a debt modification and the Company capitalized incremental debt issuance costs. Furthermore, the Agreement also provided the Company with a new $10.0 million revolving credit (the “Revolving Line”), which bears interest on the outstanding daily balance thereof of 0.70% above the Prime Rate (as defined in the Agreement). No amounts were outstanding under the Revolving Line as of December 31, 2021. The Agreement contains certain financial and non-financial covenants. As of December 31, 2021, the Company was in compliance with the terms and covenants of the EWB Loan Agreement. The following is a schedule of payments due on notes payable as of December 31, 2021 (in thousands): Year Ending December 31 2022 $ 845 2023 6,617 2024 10,406 2025 4,210 Total payments due 22,078 Less: Interest payments, loan discounts and financing costs (2,316) Current portion, less loan discounts and financing costs — Notes payable, non current $ 19,762

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' equity	Stockholders’ equity The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 310,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 10,000,000 of preferred stock. Common stock Common stock issued and outstanding was 67,595,535 and 64,486,246 shares as of December 31, 2021 and 2020, respectively. Holders of common stock are entitled to one vote per share, to receive dividends when and if declared and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up and dissolution of the Company. Convertible preferred stock

Stock Compensation Plan

Stock Compensation Plan	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock compensation plan	Stock compensation plan 2011 Equity Incentive Plan Following the adoption of the 2020 Incentive Award Plan in July 2020, any awards outstanding under the 2011 Plan continue to be governed by their existing terms but no further awards may be granted under the 2011 Plan. Stock options forfeited which were issued under the 2011 Plan will automatically add to the 2020 Plan. 2020 Incentive Award Plan In July 2020, the Company’s Board of Directors approved the 2020 Incentive Award Plan (the “2020 Plan”). The 2020 Plan allows for the issuance of stock options, restricted stock units and awards, and performance stock units. As of December 31, 2021, the number of shares remaining for issuance under the 2020 Plan was 7,655,146, which includes awards granted and outstanding under the 2011 Plan that are forfeited or lapse unexercised after the effective date of the 2020 Plan. Stock options can be granted with an exercise price less than, equal to or greater than the stock’s fair value at the date of grant. The exercise price of an incentive stock option and non-qualified stock option granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. Stock-option awards generally have 10-year terms, except for incentive stock option awards to 10% stockholders which have 5-year terms, and awards to employees generally vest and become fully exercisable after 4 years of service from the date of grant. The Company also issues restricted stock units (RSU) and performance stock units (PSU), both of which are considered restricted stock. RSU generally vest over a four-year period with equal vesting annually. Vesting of PSU is contingent upon the attainment of certain operational or financial metrics. The Company currently uses authorized and unissued shares to satisfy share award exercises and releases. Stock option activity Stock option activity during the periods indicated is as follows (in thousands except share and per share data): Number of Weighted Weighted Aggregate Balance at December 31, 2020 9,739,334 $ 9.94 7.65 $ 774,029 Options granted 917,701 $ 44.74 Options exercised (2,882,470) $ 3.57 Options cancelled (1,028,618) $ 20.98 Options expired (13,750) $ 73.22 Balance at December 31, 2021 6,732,197 $ 15.59 7.31 $ 58,979 Unvested at December 31, 2021 2,895,068 $ 23.27 8.27 $ 16,287 Vested and exercisable at December 31, 2021 3,837,129 $ 9.80 6.59 $ 42,692 Amounts in the table above are inclusive of performance-based stock options as discussed in more detail below. During the years ended December 31, 2021, 2020 and 2019, the Company granted 917,701, 2,403,270 and 4,264,036 stock options, respectively, with a weighted-average grant date fair value of $22.43 per share, $12.09 per share and $3.24 per share, respectively. The aggregate intrinsic value of options exercised was $147.5 million, $58.3 million and $2.0 million for the years ended December 31, 2021, 2020 and 2019, respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company’s common stock at the date of exercise. At December 31, 2021 there was $28.5 million of total unrecognized compensation cost related to unvested stock options granted under the Plan, which is expected to be recognized over a weighted average period of 2.71 years. Restricted stock unit activity, including performance stock unit activity Restricted Stock Units Weighted Average Grant Date Fair Value (per share) Unvested restricted stock units at December 31, 2020 — $ — Restricted stock units granted (1) 1,084,947 $ 36.38 Restricted stock units vested (63,811) $ 50.28 Restricted stock units cancelled (114,842) $ 42.73 Unvested restricted stock units at December 31, 2021 906,294 $ 34.59 (1) Restricted stock units granted include the maximum amount of performance stock units available for issuance. The actual number of shares to be issued will depend on the relative attainment of the performance metrics. The Company estimates the fair value of its restricted stock unit awards based on the Company’s stock price on the grant date. At December 31, 2021 there was $23.7 million of total unrecognized compensation cost related to unvested restricted stock units granted under the Plan, which is expected to be recognized over a weighted average period of 3.63 years. Stock-based compensation expense Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands): Year ended December 31, 2021 2020 2019 Cost of sales $ 254 $ 290 $ — Research and development 5,672 5,201 1,672 General and administrative 8,224 3,377 1,763 Sales and marketing 7,072 2,049 325 Total stock-based compensation $ 21,222 $ 10,917 $ 3,760 Stock-based compensation for the year ended December 31, 2020 includes $2.4 million of expense related to the modification of certain stock options related to the retirement of one of the Company’s non-executive employees, which was recognized at the time of the modification. There was no capitalized stock-based compensation during the years ended December 31, 2021 or 2020 as such costs subject to capitalization were immaterial. Stock option valuation assumptions for awards to employees and the Board of Directors The Company estimated the fair value of each employee and Board of Director stock option grant on the date of grant using the Black-Scholes option pricing model. The model assumptions include expected volatility, expected term, dividend yield, and the risk-free interest rate. The expected volatility was based on the volatility of a group of similar entities. The Company derived expected term by using the “simplified” method (the expected term is determined as the average of the time-to-vesting and contractual life of the option), as the company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. The Company based the risk-free rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the option. The Company has never paid any dividends and does not anticipate paying dividends in the foreseeable future, and therefore used an expected dividend yield of zero in the valuation model. Below are the assumptions used in this valuation, on a weighted average basis, for the periods presented: Year ended December 31, 2021 2020 2019 Expected dividend yield — % — % — % Expected volatility 57.4 % 47.3 % 44.5 % Expected term (years) 6.14 6.00 6.02 Risk-free interest rate 1.06 % 0.63 % 2.20 % Performance stock options During the year ended December 31, 2019, the Company granted 1,000,000 performance stock options to the Company’s Chief Executive Officer, which are accounted for as equity awards. The number of units that ultimately vest depends on achieving certain performance criteria and can range from 0% to 100% of the number of units granted. The performance criteria relate to nine objectives specific to the role of the executive and were established and approved by the Board of Directors. Each of the performance-based stock options represents the contingent right to receive one share of the Company’s common stock if the vesting conditions are satisfied. As of December 31, 2021, vesting conditions for 208,333 shares were satisfied and will vest over the next 12 months. Compensation expense related to these grants is based on the grant date fair value of the award and recorded from the period that achievement is determined to be probable through the stated service period associated with the award. As of December 31, 2021, two of the nine objectives had been achieved and the Company considered one other objective probable of achievement, while four of the nine objectives were not achieved by the required performance criteria date, resulting in the cancellation of 458,333 performance stock options. Stock-based compensation associated with awards to non-employees Since its inception, from time to time the Company has issued stock-based awards to non-employees, primarily in the form of stock options and restricted stock units. Stock-based compensation expense related to stock-based awards to non-employees is recognized as the stock-based awards are earned, generally through the provision of services. The Company believes that the fair value of the stock-based awards is more reliably measurable than the fair value of the services received. During the years ended December 31, 2021, 2020 and 2019, the Company granted a total of 2,994, 657,500 and 102,500 stock-based awards, respectively, to certain non-employees that generally vest over periods ranging from 1 to 3 years. Stock-based awards granted during the year ended December 31, 2020 include a grant of 250,000 performance stock options to a non-employee, which are accounted for as equity awards. The number of units that ultimately vest depends on achieving certain performance criteria and can range from 0% to 100% of the number of units granted. The performance criteria relate to seven objectives specific to the role of the non-employee and were established and approved by the Compensation Committee. Each of the performance stock options represents the contingent right to receive one share of the Company’s common stock if the vesting conditions are satisfied. As of December 31, 2021, vesting conditions for 175,000 shares were satisfied and an additional 5,000 shares were deemed probable of achieving their respective vesting condition in the future. Compensation expense related to these grants is based on the weighted average grant date fair value of the award, which was $10.14 per share, and is recorded from the period that achievement is determined to be probable through the stated service period associated with the award. As of December 31, 2021, six of the seven objectives had been achieved and the Company considered a portion of the seventh objective probable of achievement. As such, the associated expense will be recognized over the remaining service period. Stock-based compensation expense related to non-employee awards wa s $2.0 million, $2.0 million and $0.7 million for the years ended December 31, 2021, 2020 and 2019, respectively. The fair value of non-employee stock options was estimated using the following weighted-average valuation assumptions: Year ended December 31, 2021 2020 2019 Expected dividend yield (a) — % — % Expected volatility (a) 50.2 % 44.2 % Expected term (years) (a) 5.67 5.44 Risk-free interest rate (a) 0.37 % 2.20 % (a) During the year ended December 31, 2021, the Company did not grant stock options to non-employees. The assumptions for stock option grants to non-employees were determined in a matter consistent with those of the option awards granted to employees, other than the expected term, which was based on the contractual term of the award. Employee Stock Purchase Plan A total of 1,094,004 shares of the Company’s common stock were available for issuance under the 2020 Employee Stock Purchase Plan (the “ESPP”) at December 31, 2021. The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period for the ESPP ran from July 17, 2020 through March 6, 2021, with subsequent offering periods following in six month intervals. During the year ended December 31, 2021, 163,008 shares were issued under the ESPP. Total stock-based compensation recorded for the ESPP was $1.2 million and $0.7 million for the year ended December 31, 2021 and 2020 respectively. For the year ended December 31, 2021, the weighted average grant date fair value of the ESPP shares purchased, using the Black-Scholes option pricing model, was $10.40. For the year ended December 31, 2021, the fair value of the ESPP was estimated using the following weighted-average valuation assumptions: Year ended December 31, 2021 Expected dividend yield — % Expected volatility 72.1 % Expected term (years) 0.56 Risk-free interest rate 0.11 %

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income taxes For the years ended December 31, 2021, 2020 and 2019, income from continuing operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. Income tax expense (benefit) attributable to income from continuing operations consists of (in thousands): Year ended December 31, 2021 2020 2019 Current provision (benefit): Federal $ — $ — $ — State 26 70 24 Foreign (81) 104 45 Total current provision (benefit) (55) 174 69 Deferred provision: Federal — — — State — — — Foreign — — — Total deferred provision — — — Total provision (benefit) $ (55) $ 174 $ 69 Tax rate reconciliation Income tax expense (benefit) attributable to income from continuing operations was $(55,000), $174,000 and $69,000 for the years ended December 31, 2021, 2020 and 2019 , respectively, and differed from the amounts computed by applying the U.S. federal statutory income tax rate to loss from continuing operations as a result of the following (in thousands): Year ended December 31, 2021 2020 2019 Tax benefit at federal statutory rate $ (15,074) $ (8,696) $ (3,829) State income taxes (2,817) (1,012) (341) Foreign rate differential (434) 84 21 Research and development credits (3,420) (2,740) (2,312) Change in unrecognized tax benefits 1,283 1,028 867 Non-deductible stock-based compensation (21,692) (5,184) 320 Non-deductible permanent expenses 629 87 20 Other 509 306 (127) Change in valuation allowance 40,961 16,301 5,450 Provision for (benefit from) income taxes $ (55) $ 174 $ 69 Significant components of deferred taxes The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 are presented below (in thousands): December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 85,326 $ 50,435 Income tax credit carryforwards 10,471 8,333 Accruals and reserves 1,996 936 Deferred revenue 3,243 1,629 Operating lease liability 6,150 3,989 Stock-based compensation 2,578 1,352 Inventory 266 18 Total gross deferred tax assets 110,030 66,692 Less valuation allowance (102,769) (61,808) Net deferred tax assets 7,261 4,884 Deferred tax liabilities: Contract assets (636) (608) Receivables and deferred costs (226) (202) Operating lease right-of-use asset (5,876) (3,746) Depreciation expense (523) (328) Total gross deferred tax liabilities (7,261) (4,884) Net deferred tax assets $ — $ — As of December 31, 2021, the Company had federal, California and other state net operating loss carryforwards of $348.9 million, $98.1 million and $74.8 million, respectively. The federal net operating losses incurred before January 1, 2018 and California net operating losses will begin to expire in 2031. The federal net operating losses incurred in 2018 and beyond do not expire. The net operating losses in the other states will begin to expire in 2035. As of December 31, 2021, the Company had credit carryforwards of approximately $10.2 million and $8.8 million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal research and development credit carryforwards expire beginning 2031, and California state credits can be carried forward indefinitely. Management believes that, based on a number of factors, which includes the Company’s historical operating performance and accumulated deficit, it is more likely than not that the deferred tax assets will not be utilized, such that a full valuation allowance has been recorded against the Company’s deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Such assessment is required on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The valuation allowance for deferred tax assets consisted of the following activity for the years ended December 31, 2021 and 2020 (in thousands): Year ended December 31, 2021 2020 Balance, beginning of year $ 61,808 $ 45,507 Additions to valuation allowance 40,961 16,301 Balance, end of year $ 102,769 $ 61,808 The Company intends to continue maintaining a full valuation allowance on its deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. Utilization of net operating losses and tax credit carryforwards may be limited by ownership change rules, as defined in Section 382 of the Internal Revenue Code (“Section 382”). Similar rules may apply under state tax laws. Events which may cause limitations in the amount of the net operating losses that the Company may use in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company has assessed the application of Section 382 during the years ended December 31, 2021 and concluded no limitation currently applies. The Company will continue to monitor activities in the future, and in the event the Company has subsequent changes in ownership, net operating losses and research and development credit carry-overs, which are reserved by the full deferred tax asset valuation allowance, could be limited and may expire unutilized. During the years ended December 31, 2021 and 2020, the amount of gross unrecognized tax benefits increased by $1.4 million and $1.1 million, respectively. If the total amount of unrecognized tax benefits was recognized, it would not have an impact to the effective tax rate as it would be offset by the reversal of related deferred tax assets which are subject to a full valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2021 and 2020 is as follows (in thousands): Year ended December 31, 2021 2020 Balance, beginning of year $ 5,972 $ 4,836 Increase related to current year tax positions 1,418 1,136 Balance, end of year $ 7,390 $ 5,972 The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. To date, such interest and penalties have not been material.

Statements of Cash Flows

Statements of Cash Flows	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Statements of cash flows	Statements of cash flows The supplemental cash flow information consists of the following (in thousands): Year ended December 31, 2021 2020 2019 Cash paid for interest $ 969 $ 1,368 $ 1,361 Cash paid for income taxes $ 3 $ 108 $ 109 Non cash investing and financing activities: Inventory transferred to property and equipment (1) $ 2,705 $ — $ — Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 828 $ (118) $ 43 Release of repurchase rights on early exercised options $ — $ 328 $ 88 (1) The non-cash transfer of inventory to property and equipment principally relates to Beacons that were transferred to our BioFoundry operations in the first and second quarter of 2021. As a result of the growth of our BioFoundry operations, including growth in the number of Beacons used to fulfill strategic partnerships and services agreements, beginning in the third quarter of 2021, Beacons that at inception are planned to be used in our BioFoundry operations will be categorized as “Purchase of property and equipment.”

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Licensing agreements In October of 2011, we entered into a license agreement, which was subsequently amended in March 2016 (the “UC Agreement”), with The Regents of the University of California (the “UC Regents”), pursuant to which UC Regents granted us an exclusive, sublicensable, worldwide license under certain patent rights owned by UC Regents related certain of our products. We paid UC Regents upfront payments totaling $15,000 in connection with executing the UC Agreement. In addition, we issued 250,992 shares of common stock to certain persons associated with UC Regents in July 2013. We pay UC Regents a sub-single digit percentage royalty on our net sales of certain products covered by the licensed patents, subject to an annual minimum royalty payment of $10,000. The UC Agreement will continue until the expiration of the last to expire patent or last to be abandoned patent application that is licensed to us, unless terminated earlier in accordance with the terms of the UC Agreement. Legal proceedings From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred. AbCellera Biologics Litigation In July 2020, AbCellera Biologics Inc. (“AbCellera”) filed a complaint in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936 and 10,704,018 (“AbCellera I”). In August 2020, AbCellera filed a second complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,718,768, 10,738,270, 10,746,737, and 10,753,933 (“AbCellera II”). In September 2020, AbCellera filed amended complaints in each of AbCellera I and AbCellera II adding The University of British Columbia (“UBC”) as a named plaintiff. Also in September 2020, AbCellera and UBC filed a third complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,775,376, 10,775,377, and 10,775,378 (“AbCellera III”). AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the AbCellera I, AbCellera II and AbCellera III lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents and for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct. The Company filed a motion to transfer the AbCellera I, AbCellera II and AbCellera III lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (the “consolidated lawsuit”). On May 6, 2021, and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. On July 1, 2021, the court granted the Company’s motion to amend its answer and counterclaims to add federal and state unfair competition counterclaims against AbCellera Biologics; on July 22, 2021, the Company filed its amended answer and counterclaims. Also on July 1, 2021 the court issued a Case Management Order that, among other things, scheduled a jury trial date of December 12, 2022, and requires AbCellera and UBC to reduce the number of asserted patents to no more than two, and the total asserted patent claims to no more than four per patent prior to the trial. Also in July 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the United States Patent & Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent No. 10,421,936, then filed a motion in the district court to stay the consolidated lawsuit pending the outcome of the IPR proceedings. In August 2021, the Company filed a third petition for IPR with the USPTO, challenging the validity of all asserted claims of U.S. Patent No. 10,739,270. Also in August 2021, the court granted the Company’s motion to stay the consolidated AbCellera I, AbCellera II, and AbCellera III lawsuits pending the outcome of the IPR proceedings. In January 2022, the Patent Trial and Appeal Board (“PTAB”) of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10.421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. In August 2020, the Company filed a complaint in the United States District Court for the Northern District of California against AbCellera and Lineage BioSciences, Inc., an entity previously acquired by AbCellera (“AbCellera IV”). The complaint included two counts of unfair competition and one count of a declaratory judgment of non-infringement of U.S. Patent No. 10,058,839. The Company was seeking, among other things, damages and a judgment of non-infringement. In October 2020, the Company filed an amended complaint asserting the same three counts and AbCellera and Lineage filed a motion to dismiss the amended complaint, which was granted, without prejudice, in part. In light of the Company’s amended answer and counterclaims in the consolidated lawsuits, which were amended to include its federal and state unfair competition claims as discussed above, in July 2021 the Company filed a notice of dismissal without prejudice in the AbCellera IV lawsuit, resulting in its termination. The Company believes that the patent assertions by AbCellera and UBC are without merit and intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of its products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. Securities Class Action In December 2021, Victor J. Ng filed a securities class action on behalf of all purchasers of Berkeley Lights common stock between July 17, 2020 and September 14, 2021, inclusive, alleging that the Company and certain of the Company’s current and former senior executives had violated §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder (the “Securities Class Action”). The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. No provision has been made for litigation because the Company believes that it is not probable that a liability had been incurred as of December 31, 2021. The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity. Purchase commitments The Company has entered into various purchase agreements, including inventory-related agreements with its contract manufacturers. Once these orders are placed, they are generally cancelable by providing notice prior to the expected ship date, however such cancellations could result in the Company incurring certain charges depending on the timing. The Company had non-cancellable purchase obligations to contract manufacturers and other suppliers of $43.6 million at December 31, 2021. Product warranty The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the consolidated balance sheets (in thousands): December 31, 2021 2020 2019 Balance, beginning of period $ 1,271 $ 1,065 $ 601 Adjustments to existing warranties (707) (490) (159) Provision for new warranties 1,217 1,440 1,430 Settlement of pre-existing warranties (696) (744) (807) Balance, end of period $ 1,085 $ 1,271 $ 1,065

Net Loss Attributable to Common

Net Loss Attributable to Common Stockholders Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net loss attributable to common stockholders per share	Net loss attributable to common stockholders per share Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards. Awards granted with performance conditions are excluded from the shares used to compute diluted earnings per share until the performance conditions associated with the awards are met. The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Year ended December 31, 2021 2020 2019 Numerator Net loss $ (71,724) $ (41,584) $ (18,302) Cumulative undeclared dividends on Series D convertible preferred stock — (1,735) (3,198) Net loss attributable to common stockholders, basic and diluted $ (71,724) $ (43,319) $ (21,500) Denominator Weighted-average shares used to compute net income per share, basic and diluted 66,707,129 31,192,752 2,883,950 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (1.08) $ (1.39) $ (7.46) Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: Year ended December 31, 2021 2020 2019 Convertible preferred stock (on an if-converted basis) — — 50,462,272 Options to purchase common stock 6,732,197 9,739,334 9,308,036 Restricted stock units 906,294 — — Restricted shares of common stock related to early exercise of options — — 36,875 Warrants to purchase Series C convertible preferred stock — — 136,519 Total 7,638,491 9,739,334 59,943,702

Equity Method Investment in Joi

Equity Method Investment in Joint Venture	12 Months Ended
	Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Equity method investment in joint venture	Equity method investment in joint venture In 2018, Berkeley Lights entered into agreements with MDACC to form a joint venture, Optera, the purpose of which is, in part, to develop and standardize workflows and protocols to enable healthcare providers to implement proof of concept and/or clinical study protocols and cell processing to select and manipulate immune cells using the Company’s technology. Both Berkeley Lights and MDACC received 50% ownership of Optera in consideration for legal fees incurred to set up the new company. In each of the years ended December 31, 2019 and 2018, the Company entered into a note receivable of $1.0 million, for a total of $2.0 million (see Note 17 to these consolidated financial statements). The Company accounted for its investment and financial interests in Optera using the equity method of accounting and included the Company’s proportionate share of the net loss in its consolidated net loss in the statement of operations and comprehensive loss. The total equity loss recorded under this arrangement was $0.8 million during the year ended December 31, 2019, which was recorded in other income (expense), net in the consolidated statements of operations and comprehensive loss. This loss was recorded as a reserve against the note receivable balances as these amounts were considered part of the Company’s investment in Optera. Summarized financial information for Optera consisted of the following: (in thousands): Year ended December 31, 2019 Total assets $ 18 Total liabilities $ 18 Operating expenses $ 935 Net loss $ 843

Convertible Note Receivable and

Convertible Note Receivable and Embedded Derivative	12 Months Ended
	Dec. 31, 2021
Receivables [Abstract]
Convertible note receivable and embedded derivative	Convertible note receivable and embedded derivative In 2018, the Company entered into a note agreement with Optera (the “Optera Note”, see Note 16 to these consolidated financial statements). The Optera Note, which had an original maturity date in April 2019 and carried interest at 4.0%, was amended in December 2018 to extend the maturity date to October 2019. These notes convert automatically into the equity securities issued in the next Optera equity financing round greater than $20.0 million at a 20% discount to the issuance price. Alternatively, upon change of control or IPO, at the option of the holder the notes will either a) become and due and payable in cash or b) convert into common shares. Total amounts issued under the Optera Note were $2.0 million through the year ended December 31, 2019. The balance of the notes receivable, which are reported as prepaid and other current assets in the consolidated balance sheets, was $10,000 at December 31, 2021 and 2020. The discounted conversion rate in the Optera Note is considered a redemption feature that is an embedded derivative requiring bifurcation and separate accounting at its estimated fair value. The estimated fair value of the embedded derivative upon issuance in April 2018 was an asset of $0.2 million. The estimated fair value of this derivative instrument was recognized as a note discount and as an embedded derivative asset on the consolidated balance sheet upon issuance. The Company amortized the note discount into interest income using the effective interest method. Total amortization of the note discount was $60,000 for the year ended December 31, 2019. The Company estimated the fair value of the embedded derivative based on the estimated cash flows associated with the note receivable. The inputs used to determine the estimated fair value of the embedded derivative instrument included the probability of an underlying event triggering the redemption event and its timing prior to the maturity date of the Optera Note. The fair value measurement was based upon significant inputs not observable in the market. These assumptions were inherently subjective and involve significant management judgement.

Segments

Segments	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segments	Segments Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has one operating segment. The Company’s principal operations and decision-making functions are located in the United States. The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Year ended December 31, 2021 2020 2019 North America $ 41,231 $ 32,544 $ 29,862 Asia Pacific (1) 35,215 19,383 14,454 Europe 8,942 12,376 12,377 $ 85,388 $ 64,303 $ 56,693 (1) Asia Pacific includes Australia. As of December 31, 2021 and 2020, substantially all of the Company’s long-lived assets are located in the United States.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the estimate of the standalone selling price of performance obligations and allocation of contract price in multiple-element revenue arrangements, total expected costs associated with development agreements, estimated transaction price, including variable consideration, of the Company’s revenue contracts, accruals for product warranties, the fair value of equity awards and related share-based compensation, the collectability of accounts receivable, valuation of inventory and the realizability of deferred income taxes. Actual results could significantly differ from those estimates.
Cash and cash equivalents and restricted cash	Cash and cash equivalents and restricted cash The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Trade accounts receivable	Trade accounts receivable Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance and expected credit losses related to its receivables, management considers historical losses adjusted to take into account current market and economic conditions and the Company’s customers’ respective financial conditions, the amounts of receivables in dispute and the current receivables aging and current payment patterns. To the extent identified, account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Inventory	Inventory Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities and equipment and overhead.
Revenue recognition	Revenue recognition The Company derives revenue from primarily two sources, product and service revenues, which are discussed further below. The Company recognizes revenue using a five step process. This process involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract based on their stand-alone selling price, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company’s agreements with customers often include multiple performance obligations, which can sometimes be included in separate contracts entered into within a reasonably short period of time. The Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition. Management must apply judgment in determining whether the individual promises represent multiple performance obligations, or a single, combined performance obligation. In order to determine the stand-alone selling price, the Company conducts a periodic analysis to determine whether various goods or services have an observable stand-alone selling price as well as to identify significant changes to current stand-alone selling prices. If the Company does not have an observable stand-alone selling price for a particular good or service, then the stand-alone selling price for that particular good or service is estimated using an approach that maximizes the use of observable inputs. The Company’s process for determining stand-alone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. The Company believes that this method results in an estimate that represents the price the Company would charge for the product offerings if they were sold separately. For most of its performance obligations, the Company has established stand-alone selling price as a range rather than a single value, such range being plus or minus 15% of the weighted average of observable prices. If the contractually stated prices of all the performance obligations in a contract fall within their respective stand-alone selling price ranges, the Company will allocate the transaction price at the contractually stated amounts. In situations where the contractually stated price for one or more performance obligations in a contract fall(s) outside of their respective stand-alone selling price range, the Company will use the mid-point of the respective stand-alone selling price range for performance obligations in the contract priced outside of their respective stand-alone selling price range(s) and the contract values for performance obligations priced within their respective stand-alone selling price range(s), to allocate the transaction price on a relative stand- alone selling price basis. Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales. In certain markets, our products are sold to customers primarily through distributors. The terms of sales transactions to our distributors are substantially consistent with the terms of our direct sales to end customers. The following describes the nature of the Company’s primary types of revenue and the revenue recognition policies and significant payment terms as they pertain to the types of transactions the Company enters into with its customers. Product revenues Product revenues are comprised of two major revenue streams, direct platform sales and consumables. Direct platform sales revenues are comprised of advanced automation systems, which include the Beacon and Lightning systems (including fully paid workflow licenses) as well as Culture Station instruments. Consumables revenues are comprised of OptoSelect chips required to run the system as well as reagent kits. Direct platform sales also include revenue from certain historical subscription arrangements in which customers are able to subscribe to a specific workflow and pay a quarterly fee over a fixed period of time which covers the annual workflow license, the advanced automation system, as well as warranty and service. While the majority of the Company’s revenue under its TechAccess subscription falls into the service category, consumables and certain other deliverables under TechAccess subscription are categorized as product revenue. The Company’s standard arrangement with its customers is generally a purchase order or an executed contract. Revenue on product sales is recognized when control has transferred to the customer which typically occurs when the product has been shipped to the customer, risk of loss has transferred to the customer and the Company has a present right to payment for the system, chip or kit, as applicable. In certain limited circumstances when a product sale includes client acceptance provisions, the Company will first assess such terms to determine if the control of the good is being transferred to the customer in accordance with the agreed-upon specifications in the contract. To the extent that such acceptance provisions can be objectively determined to be aligned with the standard specifications of the arrangement, are defined and easily evaluated for completion, as well as do not afford the customer any additional rights or create additional performance obligations for the Company, such provisions would be determined perfunctory and would not preclude revenue recognition presuming all other criteria are met. If such acceptance provisions are considered to be substantive, revenue is recognized either when client acceptance has been obtained, client acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the client acceptance provisions have been satisfied. Payment terms are generally thirty to ninety days from the date of invoicing. On a limited basis, the Company also enters into fixed-term sales-type lease arrangements with certain qualified customers. Service revenues Service revenues primarily consist of strategic partnerships and services agreements, service and warranty, training and installation services, platform support and feasibility studies on the Company’s advanced automation systems and workflows. Strategic partnerships and services agreements are agreements whereby the Company provides services for, among other things, the development of customized workflows, screening capabilities, or for customized consumables or advanced automation systems to meet a specific customer’s needs. These contracts can be executed on a time-and-materials basis and in certain cases include defined milestones associated with these development activities over extended periods of time, some in excess of twenty-four months. The Company’s services are generally provided primarily on a fixed fee basis with defined billing schedules. The Company reviews strategic partnerships and services agreements for revenue recognition at contract inception and generally recognizes revenue from these contracts over time, using either an input measure of progress based on costs incurred to date relative to total expected costs or on a time and materials basis. The Company recognizes revenue from the sale of extended warranty and enhanced service warranty arrangements over the respective period, while revenue on feasibility studies is recognized over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Revenue on platform support is recognized as the services are performed. Service contracts are typically short-term in nature. Payment terms are generally thirty to ninety days from the date of invoicing. The Company only includes variable consideration in the transaction price to the extent that it is not probable that a significant reversal of revenue will occur for that amount. The constraint estimate is reassessed at each reporting date until the uncertainty is resolved. Contract assets and contract liabilities Contract assets include amounts where revenue recognized exceeds the amount invoiced to the customer and the right to payment is not solely subject to the passage of time. The Company’s contract asset balances of $2.8 million and $2.7 million as of December 31, 2021 and 2020, respectively, are primarily from its sales-type lease arrangements as well as its development and feasibility study agreements. The Company does not have impairment losses associated with contracts with customers for the years ended December 31, 2021 and 2020. Contract liabilities consist of fees invoiced or paid by the Company’s customers for which the associated services have not been performed and revenues have not been recognized based on the Company’s revenue recognition criteria described above. Such amounts are reported as deferred revenue on the consolidated balance sheets. Deferred revenue that is expected to be recognized during the following twelve months is recorded as a current liability and the remaining portion is recorded as non-current. Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term on the consolidated balance sheet based on the timing of when the Company expects to complete the related performance obligations and invoice the customers. Contract liabilities are classified as current or long-term on the consolidated balance sheet based on the timing when the revenue recognition associated with the related customer payments and invoicing is expected to occur. Costs to obtain or fulfill a contract Origination costs relate primarily to sales commissions to individuals that are directly related to sales transactions. Fulfillment costs generally include the direct cost of services such as platform support and feasibility studies.
Property and equipment	Property and equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation on plant and equipment is calculated on the straight-line method over the estimated useful lives of the assets. Expenditures for major additions and improvements to property and equipment are capitalized and maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. The estimated useful lives of the Company’s property and equipment are as follows: Equipment, tooling and molds 5—7 years Computer equipment and software 3—7 years Furniture, fixtures and other 3—7 years Leasehold Improvements Shorter of lease term or estimated useful life
Other assets	Other assets Other current assets and other assets consist primarily of contract assets discussed above, prepaid rent, prepaid insurance and advance payments made to certain vendors for future delivery of goods or services and software implementation costs for cloud-based hosting arrangements that are a service contract. The Company expenses all cloud-based hosting arrangement related costs (internal and external) that were incurred in the planning and post-implementation operation stages of such implementations and capitalizes costs related to the application development stage of such projects. Such projects primarily include the implementation of a new customer relationship management system (“CRM system”) and a new enterprise resource planning system (“ERP system”). The capitalized costs are generally amortized on a straight-line basis over the estimated useful life
Research and development costs	Research and development costs Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, laboratory supplies, materials expenses and allocated facilities costs for employees and contractors engaged in development arrangements, research, regulatory affairs, and product development. The Company expenses all research and development costs in the periods in which they are incurred.
Advertising expenses	Advertising expenses The cost of advertising, marketing and media is expensed as incurred.
Income taxes	Income taxes The Company’s provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflects its best assessment of estimated future taxes to be paid. The Company’s provision for income taxes consists primarily of foreign taxes and state taxes in the United States. As the Company expands the scale and scope of its international business activities, any changes in the United States and foreign taxation of such activities may increase its overall provision for income taxes in the future. Deferred income taxes comprise the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carryforwards, and other tax credits measured by applying currently enacted tax laws. A valuation allowance is provided when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company’s policy for interest and penalties related to uncertain tax positions is to recognize interest and penalties, if any, as a component of the provision for income taxes in the consolidated statements of operations and to include accrued interest and penalties within the related tax liability line in the consolidated balance sheets. For all periods presented, the Company has provided a valuation reserve equal to 100% of its deferred tax assets as the Company is not in a position to determine if its operating plans will be successful and result in taxable income to absorb any loss carryforwards.
Stock-based compensation	Stock-based compensation The Company maintains an incentive compensation plan under which incentive stock options, non-qualified stock options and restricted stock units (“RSU”) are granted primarily to employees and non-employee consultants. Stock-based compensation expense for stock-based awards is based on the grant date fair value of the award. The Company determines the fair value of RSU’s based on the closing value of its stock price listed on the Nasdaq at the date of the grant. The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period, provided
Long-lived assets	Long-lived assets Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Fair value measurements	Fair value measurements The fair value of the Company’s money market funds are based on quoted market prices in active markets for identical assets (see Note 6 to these consolidated financial statements).
Product warranties	Product warranties The Company provides a 13-month assurance-type warranty, generally beginning on the shipment date, on its platforms and chip consumables. Upon shipment, the Company establishes an accrual for estimated warranty expenses based on historical data and trends of product reliability and costs of repairing and replacing defective products. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, estimated repair costs, freight, material, labor, and overhead costs. While management believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company’s products could result in actual expenses that are below those currently estimated.
Foreign currency translation and transactions	Foreign currency translation and transactions The Company has determined that the functional and reporting currency for its operations in the United Kingdom and China is the U.S. Dollar. Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net.
Leases	Leases The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current a ssets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the consolidated balance sheets.
Leases	Leases The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date. The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current a ssets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the consolidated balance sheets.
Net loss attributable to common stockholders per share	Net loss attributable to common stockholders per share Net loss attributable to common stockholders per share is computed dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. In computing diluted net loss per share, the Company utilizes the treasury stock method.
Recently issued and adopted accounting standards	Recently issued and adopted accounting standards In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxe s, which removes certain exceptions related to intra-period tax allocations and deferred tax accounting on outside basis differences in foreign subsidiaries and equity method investments. Additionally, it provides other simplifying measures for the accounting for income taxes. The Company adopted ASU 2019-12 effective January 1, 2021; such adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of cash and cash equivalents and restricted cash	The following table provides a reconciliation of cash and cash equivalents and restricted cash on the consolidated balance sheets to the totals presented on the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 178,096 $ 233,408 Restricted cash 270 270 Total cash and cash equivalents and restricted cash as presented on the consolidated statements of cash flows $ 178,366 $ 233,678
Schedule of cash and cash equivalents and restricted cash	The following table provides a reconciliation of cash and cash equivalents and restricted cash on the consolidated balance sheets to the totals presented on the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 178,096 $ 233,408 Restricted cash 270 270 Total cash and cash equivalents and restricted cash as presented on the consolidated statements of cash flows $ 178,366 $ 233,678
Schedule of property and equipment	The estimated useful lives of the Company’s property and equipment are as follows: Equipment, tooling and molds 5—7 years Computer equipment and software 3—7 years Furniture, fixtures and other 3—7 years Leasehold Improvements Shorter of lease term or estimated useful life Property and equipment, net comprised the following (in thousands): December 31, 2021 2020 Equipment, tooling and molds $ 33,972 $ 21,118 Computer software and equipment 3,019 2,153 Furniture, fixtures and other 1,891 1,739 Leasehold improvements 6,105 5,597 Construction in process 4,803 275 Total property and equipment $ 49,790 $ 30,882 Less: accumulated depreciation (21,798) (16,338) Property and equipment, net $ 27,992 $ 14,544

Revenue From Contract With Cu_2

Revenue From Contract With Customers (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following table depicts the disaggregation of revenue by type of customer or sales channel, market segment as defined by nature of workflows and activities of the end customer, and timing of revenue recognition (in thousands): Year ended December 31, 2021 2020 2019 Type of Sales Channel Direct sales channel $ 56,969 $ 58,233 $ 53,014 Distributor channel 28,419 6,070 3,679 Net revenues $ 85,388 $ 64,303 $ 56,693 Market Segment Antibody therapeutics $ 64,317 $ 51,782 $ 49,428 Gene therapy 7,108 — — Agricultural biology 2,183 — — Cell therapy 2,818 4,472 2,550 Synthetic biology 8,962 8,049 4,715 Net revenues $ 85,388 $ 64,303 $ 56,693 Timing of Revenue Recognition Goods and services transferred at a point in time $ 55,389 $ 50,583 $ 43,359 Goods and services transferred over time 29,999 13,720 13,334 Net revenues $ 85,388 $ 64,303 $ 56,693
Schedule of receivables, contract assets and deferred revenue from contracts with customers	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): December 31, 2021 2020 Trade accounts receivable $ 25,942 $ 12,939 Contract assets, which are included in “Prepaid expenses and other current assets” $ 1,736 $ 1,310 Contract assets, long-term, which are included in “Other assets” $ 1,070 $ 1,375 Deferred revenue (current) $ 12,128 $ 5,482 Deferred revenue (non-current) $ 2,187 $ 1,709
Schedule of sales-type lease maturity	The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of December 31, 2021 (in thousands): Year ending December 31, Sales-Type 2022 $ 2,548 2023 445 2024 and thereafter 853 Total undiscounted cash flows 3,846 Less: unearned income (439) Total amounts due from customers, gross $ 3,407

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	The following table shows the components of inventory (in thousands): December 31, 2021 2020 Raw materials $ 8,296 $ 6,675 Finished goods 6,251 4,372 Total $ 14,547 $ 11,047
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets The following table shows the components of prepaid expenses and other current assets (in thousands): December 31, 2021 2020 Contract asset $ 1,736 $ 1,310 Vendor deposits 2,802 1,346 Deferred costs 561 292 Prepaid insurance 2,944 2,401 Other (1) 3,942 2,826 Total $ 11,985 $ 8,175 (1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities The following table shows the components of accrued expenses and other current liabilities (in thousands): December 31, 2021 2020 Accrued payroll and employee related expenses $ 6,757 $ 4,152 Lease liability—short-term 2,941 1,909 Accrued product warranty 1,085 1,271 Accrued legal expenses 504 606 Other 1,138 463 Total $ 12,425 $ 8,401

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): December 31, 2021 Quoted prices Significant Significant Assets Money market funds $ 25,138 $ 25,138 $ — $ — Total $ 25,138 $ 25,138 $ — $ — December 31, 2020 Quoted prices Significant Significant Assets Money market funds $ 25,133 $ 25,133 $ — $ — Total $ 25,133 $ 25,133 $ — $ —
Schedule of financial instruments not measured at fair value	The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): December 31, 2021 2020 Carrying Fair value Carrying Fair value Long-term debt, including current maturities $ 19,762 $ 19,298 $ 19,895 $ 19,949

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	The estimated useful lives of the Company’s property and equipment are as follows: Equipment, tooling and molds 5—7 years Computer equipment and software 3—7 years Furniture, fixtures and other 3—7 years Leasehold Improvements Shorter of lease term or estimated useful life Property and equipment, net comprised the following (in thousands): December 31, 2021 2020 Equipment, tooling and molds $ 33,972 $ 21,118 Computer software and equipment 3,019 2,153 Furniture, fixtures and other 1,891 1,739 Leasehold improvements 6,105 5,597 Construction in process 4,803 275 Total property and equipment $ 49,790 $ 30,882 Less: accumulated depreciation (21,798) (16,338) Property and equipment, net $ 27,992 $ 14,544

Leases (Table)

Leases (Table)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of operating lease liabilities maturity	Future payments associated with the Company’s operating lease liabilities as of December 31, 2021 are as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, 2022 $ 4,202 2023 4,276 2024 4,355 2025 4,486 2026 4,621 Thereafter 12,223 Total undiscounted lease payments 34,163 Less: implied interest (5,459) Less: tenant improvement allowance receivable (1,426) Present value of operating lease payments 27,278 Less: current portion (1) (2,941) Total long-term operating lease liabilities $ 24,337
Schedule of supplemental cash flow information related to operating leases	The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Year ended December 31, 2021 Right-of-use assets obtained for new operating lease liabilities - New leases $ 3,348 Right-of-use assets obtained in exchange for new operating lease liabilities - Modification of existing leases $ 8,320 Cash paid for amounts included in the measurement of lease liabilities $ 3,675
Schedule of additional information related to operating leases	The following summarizes additional information related to operating leases: Year ended December 31, 2021 Weighted-average remaining lease term (years) 7.51 Weighted average discount rate 4.67 %

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of payments due on notes payable	The following is a schedule of payments due on notes payable as of December 31, 2021 (in thousands): Year Ending December 31 2022 $ 845 2023 6,617 2024 10,406 2025 4,210 Total payments due 22,078 Less: Interest payments, loan discounts and financing costs (2,316) Current portion, less loan discounts and financing costs — Notes payable, non current $ 19,762

Stock Compensation Plan (Tables

Stock Compensation Plan (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	Stock option activity during the periods indicated is as follows (in thousands except share and per share data): Number of Weighted Weighted Aggregate Balance at December 31, 2020 9,739,334 $ 9.94 7.65 $ 774,029 Options granted 917,701 $ 44.74 Options exercised (2,882,470) $ 3.57 Options cancelled (1,028,618) $ 20.98 Options expired (13,750) $ 73.22 Balance at December 31, 2021 6,732,197 $ 15.59 7.31 $ 58,979 Unvested at December 31, 2021 2,895,068 $ 23.27 8.27 $ 16,287 Vested and exercisable at December 31, 2021 3,837,129 $ 9.80 6.59 $ 42,692
Schedule of restricted stock unit activity	Restricted Stock Units Weighted Average Grant Date Fair Value (per share) Unvested restricted stock units at December 31, 2020 — $ — Restricted stock units granted (1) 1,084,947 $ 36.38 Restricted stock units vested (63,811) $ 50.28 Restricted stock units cancelled (114,842) $ 42.73 Unvested restricted stock units at December 31, 2021 906,294 $ 34.59 (1) Restricted stock units granted include the maximum amount of performance stock units available for issuance. The actual number of shares to be issued will depend on the relative attainment of the performance metrics.
Schedule of stock-based compensation	Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands): Year ended December 31, 2021 2020 2019 Cost of sales $ 254 $ 290 $ — Research and development 5,672 5,201 1,672 General and administrative 8,224 3,377 1,763 Sales and marketing 7,072 2,049 325 Total stock-based compensation $ 21,222 $ 10,917 $ 3,760
Schedule of stock option valuation assumptions	Below are the assumptions used in this valuation, on a weighted average basis, for the periods presented: Year ended December 31, 2021 2020 2019 Expected dividend yield — % — % — % Expected volatility 57.4 % 47.3 % 44.5 % Expected term (years) 6.14 6.00 6.02 Risk-free interest rate 1.06 % 0.63 % 2.20 % The fair value of non-employee stock options was estimated using the following weighted-average valuation assumptions: Year ended December 31, 2021 2020 2019 Expected dividend yield (a) — % — % Expected volatility (a) 50.2 % 44.2 % Expected term (years) (a) 5.67 5.44 Risk-free interest rate (a) 0.37 % 2.20 % (a) During the year ended December 31, 2021, the Company did not grant stock options to non-employees.
Schedule of employee stock purchase plan valuation assumptions	For the year ended December 31, 2021, the fair value of the ESPP was estimated using the following weighted-average valuation assumptions: Year ended December 31, 2021 Expected dividend yield — % Expected volatility 72.1 % Expected term (years) 0.56 Risk-free interest rate 0.11 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of income tax expense	Income tax expense (benefit) attributable to income from continuing operations consists of (in thousands): Year ended December 31, 2021 2020 2019 Current provision (benefit): Federal $ — $ — $ — State 26 70 24 Foreign (81) 104 45 Total current provision (benefit) (55) 174 69 Deferred provision: Federal — — — State — — — Foreign — — — Total deferred provision — — — Total provision (benefit) $ (55) $ 174 $ 69
Schedule of effective income tax rate reconciliation	Income tax expense (benefit) attributable to income from continuing operations was $(55,000), $174,000 and $69,000 for the years ended December 31, 2021, 2020 and 2019 , respectively, and differed from the amounts computed by applying the U.S. federal statutory income tax rate to loss from continuing operations as a result of the following (in thousands): Year ended December 31, 2021 2020 2019 Tax benefit at federal statutory rate $ (15,074) $ (8,696) $ (3,829) State income taxes (2,817) (1,012) (341) Foreign rate differential (434) 84 21 Research and development credits (3,420) (2,740) (2,312) Change in unrecognized tax benefits 1,283 1,028 867 Non-deductible stock-based compensation (21,692) (5,184) 320 Non-deductible permanent expenses 629 87 20 Other 509 306 (127) Change in valuation allowance 40,961 16,301 5,450 Provision for (benefit from) income taxes $ (55) $ 174 $ 69
Schedule of deferred tax assets and liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2021 and 2020 are presented below (in thousands): December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 85,326 $ 50,435 Income tax credit carryforwards 10,471 8,333 Accruals and reserves 1,996 936 Deferred revenue 3,243 1,629 Operating lease liability 6,150 3,989 Stock-based compensation 2,578 1,352 Inventory 266 18 Total gross deferred tax assets 110,030 66,692 Less valuation allowance (102,769) (61,808) Net deferred tax assets 7,261 4,884 Deferred tax liabilities: Contract assets (636) (608) Receivables and deferred costs (226) (202) Operating lease right-of-use asset (5,876) (3,746) Depreciation expense (523) (328) Total gross deferred tax liabilities (7,261) (4,884) Net deferred tax assets $ — $ —
Summary of valuation allowance	The valuation allowance for deferred tax assets consisted of the following activity for the years ended December 31, 2021 and 2020 (in thousands): Year ended December 31, 2021 2020 Balance, beginning of year $ 61,808 $ 45,507 Additions to valuation allowance 40,961 16,301 Balance, end of year $ 102,769 $ 61,808
Schedule of unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December 31, 2021 and 2020 is as follows (in thousands): Year ended December 31, 2021 2020 Balance, beginning of year $ 5,972 $ 4,836 Increase related to current year tax positions 1,418 1,136 Balance, end of year $ 7,390 $ 5,972

Statements of Cash Flows (Table

Statements of Cash Flows (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of cash flow, supplemental disclosures	The supplemental cash flow information consists of the following (in thousands): Year ended December 31, 2021 2020 2019 Cash paid for interest $ 969 $ 1,368 $ 1,361 Cash paid for income taxes $ 3 $ 108 $ 109 Non cash investing and financing activities: Inventory transferred to property and equipment (1) $ 2,705 $ — $ — Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 828 $ (118) $ 43 Release of repurchase rights on early exercised options $ — $ 328 $ 88 (1) The non-cash transfer of inventory to property and equipment principally relates to Beacons that were transferred to our BioFoundry operations in the first and second quarter of 2021. As a result of the growth of our BioFoundry operations, including growth in the number of Beacons used to fulfill strategic partnerships and services agreements, beginning in the third quarter of 2021, Beacons that at inception are planned to be used in our BioFoundry operations will be categorized as “Purchase of property and equipment.”

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of product warranty liability	The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the consolidated balance sheets (in thousands): December 31, 2021 2020 2019 Balance, beginning of period $ 1,271 $ 1,065 $ 601 Adjustments to existing warranties (707) (490) (159) Provision for new warranties 1,217 1,440 1,430 Settlement of pre-existing warranties (696) (744) (807) Balance, end of period $ 1,085 $ 1,271 $ 1,065

Net Loss Attributable to Comm_2

Net Loss Attributable to Common Stockholders Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per common share	The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Year ended December 31, 2021 2020 2019 Numerator Net loss $ (71,724) $ (41,584) $ (18,302) Cumulative undeclared dividends on Series D convertible preferred stock — (1,735) (3,198) Net loss attributable to common stockholders, basic and diluted $ (71,724) $ (43,319) $ (21,500) Denominator Weighted-average shares used to compute net income per share, basic and diluted 66,707,129 31,192,752 2,883,950 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (1.08) $ (1.39) $ (7.46)
Schedule of antidilutive securities excluded from computation of earnings per share	The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: Year ended December 31, 2021 2020 2019 Convertible preferred stock (on an if-converted basis) — — 50,462,272 Options to purchase common stock 6,732,197 9,739,334 9,308,036 Restricted stock units 906,294 — — Restricted shares of common stock related to early exercise of options — — 36,875 Warrants to purchase Series C convertible preferred stock — — 136,519 Total 7,638,491 9,739,334 59,943,702

Equity Method Investment in J_2

Equity Method Investment in Joint Venture (Tables)	12 Months Ended
	Dec. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Summary of equity method investments	Summarized financial information for Optera consisted of the following: (in thousands): Year ended December 31, 2019 Total assets $ 18 Total liabilities $ 18 Operating expenses $ 935 Net loss $ 843

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Summary of revenue by geographic areas	The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Year ended December 31, 2021 2020 2019 North America $ 41,231 $ 32,544 $ 29,862 Asia Pacific (1) 35,215 19,383 14,454 Europe 8,942 12,376 12,377 $ 85,388 $ 64,303 $ 56,693

The Company and Basis of Pres_3

The Company and Basis of Presentation (Details) $ / shares in Units, $ in Thousands	Jul. 21, 2020USD ($)$ / sharesshares	Jul. 20, 2020shares	Jul. 10, 2020	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Net loss				$ 71,724	$ 41,584	$ 18,302
Accumulated deficit				263,608	191,884
Cash and cash equivalents				178,096	233,408
Reverse stock split ratio			0.50
Offering costs, underwriting discounts and commissions				$ 0	$ 2,650	$ 0
Convertible Preferred Stock
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Number of convertible preferred stock converted (in shares) | shares	50,462,272	50,462,272
IPO
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Number of shares sold (in shares) | shares	9,315,000
Shares offering price (in dollars per share) | $ / shares	$ 22
Net proceeds after deducting offering costs, underwriting discounts and commissions	$ 187,900
Offering costs, underwriting discounts and commissions	$ 17,000
Underwriters' Option
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Number of shares sold (in shares) | shares	1,215,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 178,096	$ 233,408
Restricted cash	270	270
Total cash and cash equivalents and restricted cash as presented on the consolidated statements of cash flows	$ 178,366	$ 233,678	$ 81,303	$ 99,887

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Revenue Recognition (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)revenueSource	Dec. 31, 2020USD ($)
Disaggregation of Revenue [Line Items]
Revenue sources	2
Percentage of median observable prices	15.00%
Contract asset | $	$ 2.8	$ 2.7
Product
Disaggregation of Revenue [Line Items]
Revenue streams	2
Payment terms	Payment terms are generally thirty to ninety days from the date of invoicing.
Service
Disaggregation of Revenue [Line Items]
Payment terms	Payment terms are generally thirty to ninety days from the date of invoicing.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Equipment, tooling and molds | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Equipment, tooling and molds | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Computer equipment and software | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Computer equipment and software | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Furniture, fixtures and other | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Furniture, fixtures and other | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Other Assets (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Property, Plant and Equipment [Line Items]
Capitalized costs	$ 0.5	$ 0.3
Other Assets
Property, Plant and Equipment [Line Items]
Capitalized costs	$ 0.5	$ 0.6

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Advertising Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Advertising expenses	$ 1.2	$ 1.4	$ 1

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Income Taxes (Details)	Dec. 31, 2021
Accounting Policies [Abstract]
Deferred tax assets, valuation reserve, percentage	100.00%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Product Warranty (Details)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Product warranty, term	13 months

Significant Risks and Uncerta_2

Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) - Customer	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	19.00%	12.00%
Revenue | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	11.00%
Revenue | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage	10.00%
Accounts Receivable | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	15.00%	42.00%
Accounts Receivable | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	11.00%	21.00%
Accounts Receivable | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage	11.00%	15.00%

Revenue From Contract With Cu_3

Revenue From Contract With Customers - Schedule of disaggregation of revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net revenues	$ 85,388	$ 64,303	$ 56,693
Goods and services transferred at a point in time
Disaggregation of Revenue [Line Items]
Net revenues	55,389	50,583	43,359
Goods and services transferred over time
Disaggregation of Revenue [Line Items]
Net revenues	29,999	13,720	13,334
Antibody therapeutics
Disaggregation of Revenue [Line Items]
Net revenues	64,317	51,782	49,428
Gene therapy
Disaggregation of Revenue [Line Items]
Net revenues	7,108	0	0
Agricultural biology
Disaggregation of Revenue [Line Items]
Net revenues	2,183	0	0
Cell therapy
Disaggregation of Revenue [Line Items]
Net revenues	2,818	4,472	2,550
Synthetic biology
Disaggregation of Revenue [Line Items]
Net revenues	8,962	8,049	4,715
Direct sales channel
Disaggregation of Revenue [Line Items]
Net revenues	56,969	58,233	53,014
Distributor channel
Disaggregation of Revenue [Line Items]
Net revenues	$ 28,419	$ 6,070	$ 3,679

Revenue From Contract With Cu_4

Revenue From Contract With Customers - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 7,200
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	14,300	$ 7,200
Contract liability , revenue recognized	5,300
Sales-type lease income	$ 2,700	$ 1,700
Sales -type lease income			$ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	48.00%
Remaining performance obligation, period	12 months

Revenue From Contract With Cu_5

Revenue From Contract With Customers - Schedule of Receivables, Contract Assets and Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Trade accounts receivable	$ 25,942	$ 12,939
Contract assets, which are included in “Prepaid expenses and other current assets”	1,736	1,310
Contract assets, long-term, which are included in “Other assets”	1,070	1,375
Deferred revenue (current)	12,128	5,482
Deferred revenue (non-current)	$ 2,187	$ 1,709

Revenue From Contract With Cu_6

Revenue From Contract With Customers - Sale-type Lease Arrangement (Details) $ in Thousands	Dec. 31, 2021USD ($)
Revenue from Contract with Customer [Abstract]
2022	$ 2,548
2023	445
2024 and thereafter	853
Total undiscounted cash flows	3,846
Less: unearned income	(439)
Total amounts due from customers, gross	$ 3,407

Balance Sheet Accounts - Invent

Balance Sheet Accounts - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 8,296	$ 6,675
Finished goods	6,251	4,372
Total	$ 14,547	$ 11,047

Balance Sheet Accounts - Prepai

Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract asset	$ 1,736	$ 1,310
Vendor deposits	2,802	1,346
Deferred costs	561	292
Prepaid insurance	2,944	2,401
Other (1)	3,942	2,826
Total	$ 11,985	$ 8,175

Balance Sheet Accounts - Accrue

Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and employee related expenses	$ 6,757	$ 4,152
Operating lease liability, current, extensible list	Total	Total
Lease liability—short-term	$ 2,941	$ 1,909
Accrued product warranty	1,085	1,271
Accrued legal expenses	504	606
Other	1,138	463
Total	$ 12,425	$ 8,401

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	$ 25,138	$ 25,133
Total	25,138	25,133
Quoted prices in active markets for identical assets (level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	25,138	25,133
Total	25,138	25,133
Significant other observable inputs (level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	0	0
Total	0	0
Significant unobservable inputs (level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	0	0
Total	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Schedule of Financial Instruments Not Measured at Fair Value) (Details) - Significant other observable inputs (level 2) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 19,762	$ 19,895
Fair value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 19,298	$ 19,949

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 49,790	$ 30,882
Less: accumulated depreciation	(21,798)	(16,338)
Property and equipment, net	27,992	14,544
Equipment, tooling and molds
Property, Plant and Equipment [Line Items]
Total property and equipment	33,972	21,118
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property and equipment	3,019	2,153
Furniture, fixtures and other
Property, Plant and Equipment [Line Items]
Total property and equipment	1,891	1,739
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	6,105	5,597
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 4,803	$ 275

Property and Equipment, net - N

Property and Equipment, net - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 5,598	$ 5,102	$ 4,842
Impairment of long-lived assets	$ 60	$ 140	$ 782

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)ft²facility	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2021
Lessee, Lease, Description [Line Items]
Area of lease (sq. ft) | ft²	84,502
Number of facilities | facility	2
Rent expense	$ 3.8	$ 2.6
Rent expense			$ 2.2
Variable lease payments	$ 2.3	$ 1.6	$ 1
Building
Lessee, Lease, Description [Line Items]
Lease term				7 years

Leases - Maturity Schedule of O

Leases - Maturity Schedule of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 4,202
2023	4,276
2024	4,355
2025	4,486
2026	4,621
Thereafter	12,223
Total undiscounted lease payments	34,163
Less: implied interest	(5,459)
Less: tenant improvement allowance receivable	(1,426)
Present value of operating lease payments	27,278
Less: current portion (1)	(2,941)	$ (1,909)
Total long-term operating lease liabilities	$ 24,337	$ 15,899

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Leases [Abstract]
Right-of-use assets obtained for new operating lease liabilities - New leases	$ 3,348
Right-of-use assets obtained in exchange for new operating lease liabilities - Modification of existing leases	8,320
Cash paid for amounts included in the measurement of lease liabilities	$ 3,675

Leases - Schedule of Additional

Leases - Schedule of Additional Information Related to Operating Leases (Details)	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (years)	7 years 6 months 3 days
Weighted average discount rate	4.67%

Notes Payable - Narrative (Deta

Notes Payable - Narrative (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	May 23, 2018
Debt Instrument [Line Items]
Interest cost		$ 1,200,000	$ 1,400,000	$ 1,400,000
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 10,000,000
Amount outstanding		$ 0
Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread	0.70%
Notes Payable | EWB Loan
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 20,000,000
Notes Payable | Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 20,000,000
Note payable, term (in years)	48 months
Interest rate	4.17%
Interest only period	24 months
Interest only period with extension	36 months

Notes Payable - Schedule of Pay

Notes Payable - Schedule of Payment Due on Notes Payable (Details) - Notes Payable - EWB Loan $ in Thousands	Dec. 31, 2021USD ($)
Debt Instrument [Line Items]
2022	$ 845
2023	6,617
2024	10,406
2025	4,210
Total payments due	22,078
Interest payments, loan discounts and financing costs	(2,316)
Current portion, less loan discounts and financing costs	0
Notes payable, non current	$ 19,762

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - shares	Jul. 21, 2020	Jul. 20, 2020	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Number of shares authorized (in shares)			310,000,000
Common stock authorized (in shares)			300,000,000
Convertible preferred stock authorized (in shares)			10,000,000
Common stock issued (in shares)			67,595,535	64,486,246
Common stock outstanding (in shares)			67,595,535	64,486,246
Convertible preferred stock outstanding (in shares)			0	0
Convertible Preferred Stock
Class of Stock [Line Items]
Number of convertible preferred stock converted (in shares)	50,462,272	50,462,272

Stock Compensation Plan - Narra

Stock Compensation Plan - Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares remaining for issuance (in shares)		7,655,146
Stock options granted in period (in shares)		917,701	2,403,270	4,264,036
Stock options granted, weighted-average grant date fair value (in dollars per share)		$ 22.43	$ 12.09	$ 3.24
Stock options exercised, aggregate intrinsic value		$ 147,500,000	$ 58,300,000	$ 2,000,000
Number of shares received per performance stock option (in shares)		1
Options cancelled (in shares)		1,028,618
Number of shares deemed probable of achieving vesting condition (in shares)		5,000
Total stock-based compensation		$ 21,222,000	$ 10,917,000	$ 3,760,000
Offering period		6 months
Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted in period (in shares)		2,994	657,500	102,500
Total stock-based compensation		$ 2,000,000	$ 2,000,000	$ 700,000
Minimum | Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Maximum | Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, unrecognized compensation cost		$ 28,500,000
Unrecognized compensation cost, period for recognition		2 years 8 months 15 days
Capitalized stock-based compensation		$ 0	$ 0
Stock options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield		0.00%	0.00%	0.00%
Stock options | Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted in period (in shares)		0
Stock-based compensation expense			$ 2,400,000
Expected dividend yield			0.00%	0.00%
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Stock option, unrecognized compensation cost		$ 23,700,000
Unrecognized compensation cost, period for recognition		3 years 7 months 17 days
ESPP weighted average grant date fair value (in dollars per share)		$ 36.38
Performance stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		12 months
Stock options granted, weighted-average grant date fair value (in dollars per share)			$ 10.14
Performance shares vested (in shares)		208,333
Options cancelled (in shares)		458,333
Performance stock option | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted in period (in shares)				1,000,000
Performance stock option | Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted in period (in shares)			250,000
Performance shares vested (in shares)		175,000
Performance stock option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		0.00%
Performance stock option | Minimum | Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		0.00%
Performance stock option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		100.00%
Performance stock option | Maximum | Non-employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		100.00%
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percent exercise price for 10% stockholders	110.00%
Expiration term for 10% stockholders	5 years
2020 Plan | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period	4 years
2020 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration term	10 years
ESPP | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 1,200,000	$ 700,000
Expected dividend yield		0.00%
Number of shares authorized (in shares)	1,094,004
Exercise price of stock option, percentage of fair value		85.00%
Shares issued (in shares)		163,008
ESPP weighted average grant date fair value (in dollars per share)		$ 10.40

Stock Compensation Plan - Stock

Stock Compensation Plan - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of options outstanding
Beginning balance (in shares)	9,739,334
Options granted (in shares)	917,701	2,403,270	4,264,036
Options exercised (in shares)	(2,882,470)
Options cancelled (in shares)	(1,028,618)
Options expired (in shares)	(13,750)
Ending balance (in shares)	6,732,197	9,739,334
Unvested (in shares)	2,895,068
Exercisable (in shares)	3,837,129
Weighted average exercise price
Beginning balance (in dollars per share)	$ 9.94
Options granted (in dollars per share)	44.74
Options exercised (in dollars per share)	3.57
Options cancelled (in dollars per share)	20.98
Options expired (in dollars per share)	73.22
Ending balance (in dollars per share)	15.59	$ 9.94
Unvested (in dollars per share)	23.27
Exercisable (in dollars per share)	$ 9.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	7 years 3 months 21 days	7 years 7 months 24 days
Options unvested, weighted average remaining contractual term	8 years 3 months 7 days
Options exercisable, weighted average remaining contractual term	6 years 7 months 2 days
Options outstanding, aggregate intrinsic value	$ 58,979	$ 774,029
Unvested, aggregate intrinsic value	16,287
Options exercisable, aggregate intrinsic value	$ 42,692

Stock Compensation Plan - Restr

Stock Compensation Plan - Restricted Stock Unit Activity (Details) - Restricted stock units	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Restricted Stock Units
Beginning balance (in shares) | shares	0
Restricted stock units granted (in shares) | shares	1,084,947
Restricted stock units vested (in shares) | shares	(63,811)
Restricted stock units cancelled (in shares) | shares	(114,842)
Ending balance (in shares) | shares	906,294
Weighted Average Grant Date Fair Value (per share)
Beginning balance (in dollars per share) | $ / shares	$ 0
Restricted stock units granted (in dollars per share) | $ / shares	36.38
Restricted stock units vested (in dollars per share) | $ / shares	50.28
Restricted stock units cancelled (in dollars per share) | $ / shares	42.73
Ending balance (in dollars per share) | $ / shares	$ 34.59

Stock Compensation Plan - Sto_2

Stock Compensation Plan - Stock-Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 21,222	$ 10,917	$ 3,760
Cost of sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	254	290	0
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	5,672	5,201	1,672
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	8,224	3,377	1,763
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 7,072	$ 2,049	$ 325

Stock Compensation Plan - Sto_3

Stock Compensation Plan - Stock Option Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
ESPP | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Expected volatility	72.10%
Expected term (years)	6 months 21 days
Risk-free interest rate	0.11%
Employee | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	57.40%	47.30%	44.50%
Expected term (years)	6 years 1 month 20 days	6 years	6 years 7 days
Risk-free interest rate	1.06%	0.63%	2.20%
Non-employee | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield		0.00%	0.00%
Expected volatility		50.20%	44.20%
Expected term (years)		5 years 8 months 1 day	5 years 5 months 8 days
Risk-free interest rate		0.37%	2.20%

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current provision (benefit):
Federal	$ 0	$ 0	$ 0
State	26	70	24
Foreign	(81)	104	45
Total current provision (benefit)	(55)	174	69
Deferred provision:
Federal	0	0	0
State	0	0	0
Foreign	0	0	0
Total deferred provision	0	0	0
Total provision (benefit)	$ (55)	$ 174	$ 69

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Provision for (benefit from) income taxes	$ (55)	$ 174	$ 69
Increase in unrecognized tax benefits	1,400	$ 1,100
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	348,900
Tax credit carryforward	10,200
State | California Franchise Tax Board
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	98,100
Tax credit carryforward	8,800
State | States Other Than California Franchise Tax Board
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 74,800

Income Taxes - Income Tax Recon

Income Taxes - Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	$ (15,074)	$ (8,696)	$ (3,829)
State income taxes	(2,817)	(1,012)	(341)
Foreign rate differential	(434)	84	21
Research and development credits	(3,420)	(2,740)	(2,312)
Change in unrecognized tax benefits	1,283	1,028	867
Non-deductible stock-based compensation	(21,692)	(5,184)	320
Non-deductible permanent expenses	629	87	20
Other	509	306	(127)
Change in valuation allowance	40,961	16,301	5,450
Total provision (benefit)	$ (55)	$ 174	$ 69

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 85,326	$ 50,435
Income tax credit carryforwards	10,471	8,333
Accruals and reserves	1,996	936
Deferred revenue	3,243	1,629
Operating lease liability	6,150	3,989
Stock-based compensation	2,578	1,352
Inventory	266	18
Total gross deferred tax assets	110,030	66,692
Less valuation allowance	(102,769)	(61,808)	$ (45,507)
Net deferred tax assets	7,261	4,884
Deferred tax liabilities:
Contract assets	(636)	(608)
Receivables and deferred costs	(226)	(202)
Operating lease right-of-use asset	(5,876)	(3,746)
Depreciation expense	(523)	(328)
Total gross deferred tax liabilities	(7,261)	(4,884)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Valuation Allowa

Income Taxes - Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Change In Valuation Allowance, Rollforward [Roll Forward]
Balance, beginning of year	$ 61,808	$ 45,507
Additions to valuation allowance	40,961	16,301
Balance, end of year	$ 102,769	$ 61,808

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of year	$ 5,972	$ 4,836
Increase related to current year tax positions	1,418	1,136
Balance, end of year	$ 7,390	$ 5,972

Statements of Cash Flows (Detai

Statements of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash paid for interest	$ 969	$ 1,368	$ 1,361
Cash paid for income taxes	3	108	109
Non cash investing and financing activities:
Inventory transferred to property and equipment	2,705	0	0
Change in accounts payable and accrued liabilities related to purchases of property and equipment	828	(118)	43
Release of repurchase rights on early exercised options	$ 0	$ 328	$ 88

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details)	Jul. 01, 2021patentclaim	Oct. 31, 2020claim	Aug. 31, 2020claim	Jul. 31, 2013shares	Oct. 31, 2011USD ($)	Dec. 31, 2021USD ($)
Loss Contingencies [Line Items]
Upfront payment | $					$ 15,000
Common stock issued (in shares) | shares				250,992
Annual minimum royalty payment | $						$ 10,000
Number of counts in amended complaint | claim		3
Loss contingency accrual | $						0
Purchase obligations | $						$ 43,600,000
AbCellera And UBC
Loss Contingencies [Line Items]
Case management order, maximum number of patents allegedly infringed | patent	2
Case management order, maximum asserted patent claims per patent | claim	4
AbCellera, Unfair Competition
Loss Contingencies [Line Items]
Counter claims filed | claim			2
AbCellera, Non-Infringement
Loss Contingencies [Line Items]
Counter claims filed | claim			1

Commitment and Contingencies _2

Commitment and Contingencies - Product Warranty (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance, beginning of period	$ 1,271	$ 1,065	$ 601
Adjustments to existing warranties	(707)	(490)	(159)
Provision for new warranties	1,217	1,440	1,430
Settlement of pre-existing warranties	(696)	(744)	(807)
Balance, end of period	$ 1,085	$ 1,271	$ 1,065

Net Loss Attributable to Comm_3

Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator
Net loss	$ (71,724)	$ (41,584)	$ (18,302)
Cumulative undeclared dividends on Series D convertible preferred stock	0	(1,735)	(3,198)
Net loss attributable to common stockholders, basic and diluted	(71,724)	(43,319)	(21,500)
Net loss attributable to common stockholders, basic and diluted	$ (71,724)	$ (43,319)	$ (21,500)
Denominator
Weighted-average shares used to compute net income per share, basic (in shares)	66,707,129	31,192,752	2,883,950
Weighted-average shares used to compute net income per share, diluted (in shares)	66,707,129	31,192,752	2,883,950
Net loss per share
Net loss attributable to common stockholders per share, basic (in dollars per share)	$ (1.08)	$ (1.39)	$ (7.46)
Net loss attributable to common stockholders per share, diluted (in dollars per share)	$ (1.08)	$ (1.39)	$ (7.46)

Net Loss Attributable to Comm_4

Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	7,638,491	9,739,334	59,943,702
Convertible preferred stock (on an if-converted basis)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	0	0	50,462,272
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	6,732,197	9,739,334	9,308,036
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	906,294	0	0
Restricted shares of common stock related to early exercise of options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	0	0	36,875
Warrants to purchase Series C convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	0	0	136,519

Equity Method Investment in J_3

Equity Method Investment in Joint Venture - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Issuance of notes receivable	$ 0	$ 0	$ 1,000
Equity method losses in Optera Therapeutics Corp.	$ 0	$ 0	806
Optera | Note Receivable, 2018
Schedule of Equity Method Investments [Line Items]
Note receivable total amounts				$ 1,000
Optera | Note Receivable, 2019
Schedule of Equity Method Investments [Line Items]
Note receivable total amounts			1,000
Optera | Notes Receivable
Schedule of Equity Method Investments [Line Items]
Note receivable total amounts			2,000
Loss on disposal and impairment of property and equipment			$ 200
Optera
Schedule of Equity Method Investments [Line Items]
Ownership percentage	50.00%

Equity Method Investment in J_4

Equity Method Investment in Joint Venture - Summary of Equity Method Investment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Total assets	$ 287,253	$ 299,658
Total liabilities	79,037	54,877
Operating expenses	127,340	84,949	$ 60,013
Net loss	$ (71,724)	$ (41,584)	(18,302)
Optera | Optera
Schedule of Equity Method Investments [Line Items]
Total assets			18
Total liabilities			18
Operating expenses			935
Net loss			$ 843

Convertible Note Receivable a_2

Convertible Note Receivable and Embedded Derivative (Details) - Optera $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Apr. 30, 2018USD ($)
Embedded Derivative
Accounts, Notes, Loans and Financing Receivable [Line Items]
Derivative asset					$ 200
Amortization of note discount	$ 60
Change in fair value of the embedded derivative	100
Loss on disposal and impairment of property and equipment	200
Notes Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate		0.040
Note receivable, converted to equity financing, greater than			$ 20,000
Note receivable converted to equity financing, discount			0.20
Note receivable total amounts	2,000
Note receivable balance			$ 10	$ 10
Loss on disposal and impairment of property and equipment	$ 200

Segments (Details)

Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | segment	1
Total revenue	$ 85,388	$ 64,303	$ 56,693
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	41,231	32,544	29,862
Asia Pacific (1)
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	35,215	19,383	14,454
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 8,942	$ 12,376	$ 12,377